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FUSION PROTEINS FORTREATING 
METABOLIC DISORDERS 
FIELD OF THE INVENTION 
0001. The present invention relates to new fusion proteins 
comprising fibroblast growth factor 21 (FGF21) known to 
improve metabolic profiles in subjects to whom they are 
administered. 
BACKGROUND OF THE INVENTION 
0002. The fibroblast growth factor (FGF) family is char 
acterized by 22 genetically distinct, homologous ligands, 
which are grouped into seven subfamilies. FGF-21 is most 
closely related to, and forms a subfamily with, FGF-19 and 
FGF-23. This FGF subfamily regulates diverse physiological 
processes uncommon to classical FGFs, namely energy and 
bile acid homeostasis, glucose and lipid metabolism, and 
phosphate as well as Vitamin D homeostasis. Moreover, 
unlike other FGFs, this subfamily acts in an endocrine fash 
ion. (Moore, D. D. (2007) Science 316, 1436-8) (Beenken et 
al. (2009) Nature Reviews Drug Discovery 8, 235). 
0003 FGF21 is a 209 amino acid polypeptide containing a 
28 amino acid leader sequence (SEQ ID NO:5). Human 
FGF21 has about 79% amino acid identity to mouse FGF21 
and about 80% amino acid identity to rat FGF21. Fibroblast 
growth factor 21 
0004 (FGF21) has been described as a treatment for 
ischemic vascular disease, wound healing, and diseases asso 
ciated with loss of pulmonary, bronchia or alveolar cell func 
tion. (Nishimura et al. (2000) Biochimica et Biophysica Acta, 
1492:203-206: patent publication WO01/36640; and patent 
publication WO01/18172) Although FGF-21 activates FGF 
receptors and downstream signaling molecules, including 
FRS2a and ERK, direct interaction of FGFRs and FGF-21 has 
not been detected. Studies have identified B-klotho, which is 
highly expressed in liver, adipocytes and pancreas, as a deter 
minant of the cellular response to FGF-21 and a cofactor 
which mediates FGF-21 signaling through FGFRs (Kurosu, 
H. et al. (2007) J Biol Chem 282, 26687-95). FGF21 is a 
potentagonist of the FGFR1 (IIIc), FGFR2(IIIc) and FGFR3 
(IIIc) B-klotho signaling complexes. 
0005 FGF-21 has been shown to induce insulin-indepen 
dent glucose uptake. FGF-21 has also been shown to amelio 
rate hyperglycemia in a range of diabetic rodent models. In 
addition, transgenic mice over-expressing FGF-21 were 
found to be resistant to diet-induced metabolic abnormalities, 
and demonstrated decreased body weight and fat mass, and 
enhancements in insulin sensitivity (Badman, M. K. et al. 
(2007) Cell Metab 5, 426-37). Administration of FGF-21 to 
diabetic non-human primates caused a decline in fasting 
plasma glucose, triglycerides, insulin and glucagon levels, 
and led to significant improvements in lipoprotein profiles 
including a nearly 80% increase in HDL cholesterol (Khari 
tonenkov, A. et al. (2007) Endocrinology 148, 774-81). 
Recent studies investigating the molecular mechanisms of 
FGF21 action have identified FGF21 as an important endo 
crine hormone that helps to control adaptation to the fasting 
state. (Badman et al. (2009) Endocrinology 150, 4931) (Ina 
gaki et al. (2007) Cell Metabolism 5, 415) This provides a 
previously missing link downstream of PPARC, by which the 
liver communicates with the rest of the body in regulating the 
biology of energy homeostasis. (Galman et al. (2008) Cell 
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Metabolism 8,169) (Lundasen et al. (2007) Biochemical and 
Biophysical Research Communications 360, 437). 
0006 FGF21 regulates adipocyte homeostasis through 
activation of an AMPK/SIRT1/PGC1C. pathway to inhibit 
PPARY expression and increase mitochondrial function. 
(Chau et al. (2010) PNAS 107, 12553) FGF21 also increases 
glucose uptake by skeletal muscle as measured in cultured 
human myotubes and isolated mouse tissue. FGF21 treatment 
of rodent islet cells leads to improved function and survival 
through activation of ERK1/2 and Akt pathways. (Wente et al. 
(2006) Diabetes 55, 2470) FGF21 treatment also results in 
altered gene expression for lipogenesis and fatty acid oxida 
tion enzymes in rodent livers, likely through HNF4C. and 
Foxa2 signaling. 
0007. A difficulty associated with using FGF-21 directly 
as a biotherapeutic is that its half-life is very short. (Khari 
tonenkov, A. et al. (2005) Journal of Clinical Investigation 
115:1627-1635) In mice, the half-life of human FGF21 is 0.5 
to 1 hours, and in cynomolgus monkeys, the half-life is 2 to 3 
hours. FGF21 may be utilized as a multi-use, sterile pharma 
ceutical formulation. However, it has been determined that 
preservatives, i.e., m-cresol, have an adverse affect on its 
stability under these conditions. 
0008. In developing an FGF21 protein for use as a thera 
peutic in the treatment of type 1 and type 2 diabetes mellitus 
and other metabolic conditions, an increase in half-life and 
stability would be desirable. FGF21 proteins having 
enhanced half-life and stability would allow for less frequent 
dosing of patients being administered the protein. Clearly, 
there is a need to develop a stable aqueous protein formula 
tion for the therapeutic protein FGF21. 
0009 Furthermore, significant challenge in the develop 
ment of FGF21 as a protein pharmaceuticals, is to cope with 
its physical and chemical instabilities. The compositional 
variety and characteristics of proteins define specific behav 
iors such as folding, conformational stability, and unfolding/ 
denaturation. Such characteristics should be addressed when 
aiming to stabilize proteins in the course of developing phar 
maceutical formulation conditions utilizing aqueous protein 
solutions (Wang, W., Int. J. of Pharmaceutics, 18, (1999)). A 
desired effect of stabilizing therapeutic proteins of interest, 
e.g., the proteins of the present invention, is increasing resis 
tance to proteolysis and enzymatic degradation, thereby 
improving protein stability and reducing protein aggregation. 
SUMMARY OF THE INVENTION 
0010. The invention relates to the identification of new 
fusion proteins which comprise fibroblast growth factor 21 
(FGF21) and which have improved pharmaceutical proper 
ties over the wild-type FGF21 and variants thereof under 
pharmaceutical formulation conditions, e.g., are more stable, 
possess the ability to improve metabolic parameters for Sub 
jects to whom they are administered, are less Susceptible to 
proteolysis and enzymatic degradation, and are less likely to 
aggregate and form complexes. The fusion proteins of the 
invention comprise truncations, mutations, and variants of 
FGF21. 
0011. Also disclosed are methods for treating FGF21-as 
Sociated disorders, as well as other metabolic, endocrine, and 
cardiovascular disorders, such as obesity, type 1 and type 2 
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic 
fatty liver disease (NAFLD), nonalcoholic steatohepatitis 
(NASH), insulin resistance, hyperinsulinemia, glucose intol 
erance, hyperglycemia, metabolic syndrome, acute myocar 
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dial infarction, hypertension, cardiovascular disease, athero 
Sclerosis, peripheral arterial disease, stroke, heart failure, 
coronary heart disease, kidney disease, diabetic complica 
tions, neuropathy, gastroparesis, disorders associated with 
severe inactivating mutations in the insulin receptor, and 
other metabolic disorders, and in reducing the mortality and 
morbidity of critically ill patients. 
0012. The fusion proteins of the present invention may be 
used as a once weekly injectable either alone or in combina 
tion with oral anti-diabetic agents which will improve the 
glycemic control, body weight and lipid profile of type 1 and 
type 2 diabetes mellitus patients. The proteins may also be 
used for the treatment of obesity or other FGF21-associated 
conditions. 
0013 The fusion proteins of the invention overcome the 
significant hurdles of physical instabilities associated with 
protein therapeutics, including, for instance, with the admin 
istration of the wild-type FGF21, by presenting proteins 
which are more stable, less Susceptible to proteolysis and 
enzymatic degradation, and less likely to aggregate and form 
complexes, than wild-type FGF21 under pharmaceutical for 
mulation conditions. 
0014. In a first aspect, the invention provides Fibroblast 
Growth Factor 21 (FGF21) fusion proteins comprising one or 
more of the sequences listed in Table 1, and further described 
herein. The FGF21 sequences listed in Table 1 may be vari 
ants of the wild-type FGF21 sequence, e.g., the wild-type 
FGF21 sequence with NCBI reference number NP 061986. 
1, and found in such issued patents as, e.g., U.S. Pat. No. 
6,716,626B1, assigned to Chiron Corporation. 
0015 Said fusions may be, for example, between the vari 
ant FGF21 sequences, e.g., the sequences of Table 1, and 
other molecules (a non-FGF21 portion), e.g., an IgG constant 
domain or fragment thereof (e.g., the Fc region), Human 
Serum Albumin (HSA), or albumin-binding polypeptides. In 
a preferred embodiment, the non-FGF21 portion of the mol 
ecule is an Fc region. 
0016 Other embodiments are drawn to polynucleotides 
encoding the fusion proteins of the invention, a vector con 
taining said polynucleotides and a host cell carrying said 
Vector. 
0017 Provided herein are methods used to generate the 
fusion proteins of the invention, wherein such methods 
involve modification of the wild-type FGF21 protein, via e.g., 
the site-specific incorporation of amino acids at positions of 
interest within the wild-type FGF21 protein, as well as the 
fusion between the FGF21 portion of the molecule to other 
molecules, e.g., an IgG constant domain or fragment thereof 
(e.g., the Fc region), Human Serum Albumin (HSA), or albu 
min-binding polypeptides. Said modifications and fusions 
enhance the biological properties of the fusion proteins of the 
invention relative to the wild-type versions of the proteins as 
well as, in some cases, serving as points of attachment for, 
e.g., labels and protein half-life extension agents, and for 
purposes of affixing said variants to the Surface of a Solid 
support. Related embodiments of the invention are methods 
to produce cells capable of producing said proteins of the 
invention, and of producing vectors containing DNA encod 
ing said variants and fusions. 
0018. In various embodiments, the fusion proteins of the 
invention disclosed herein can comprise one or more frag 
ments of the FGF21 wild-type sequences, including frag 
ments as Small as 8-12 amino acid residues in length, and 
wherein the polypeptide is capable of lowering blood glucose 
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in a mammal. In various embodiments, the fusion proteins of 
the invention disclosed herein can comprise one or more 
variant of the FGF21 wild-type sequences, e.g., with one or 
more amino acid deletion, insertion, addition, or Substitution 
relative to the wild-type sequences thereof. 
0019. In some embodiments, the fusion proteins of the 
invention disclosed herein can be covalently linked to one or 
more polymers, such as polyethylene glycol (PEG) or poly 
sialic acid, whether at the position of site-specific amino acid 
modifications made relative to the wild-type FGF21, or at the 
position of amino acids commonly shared with the wild-type 
versions of those proteins. The PEG group is attached in such 
away so as enhance, and/or not to interfere with, the biologi 
cal function of the constituent portions of the fusion proteins 
of the invention, e.g., the FGF21 protein variants. In other 
embodiments, the polypeptides of the invention can be fused 
to a heterologous amino acid sequence, optionally via a 
linker, such as GS, GGGGSGGGGSGGGGS (SEQ ID 
NO:6). The heterologous amino acid sequence can be an IgG 
constant domain or fragment thereof (e.g., the Fc region), 
Human Serum Albumin (HSA), or albumin-binding polypep 
tides. Such fusion proteins disclosed herein can also form 
multimers. 
0020. In some embodiments, a heterologous amino acid 
sequence (e.g., HSA, Fc, etc.) is fused to the amino-terminal 
of the fusion proteins of the invention. In other embodiments, 
the fusion heterologous amino acid sequence (e.g., HSA, Fc. 
etc.) is fused to the carboxyl-terminal of the fusion proteins of 
the invention. 
0021. Yet another embodiment is drawn to methods of 
treating a patient exhibiting one or more FGF21-associated 
disorders, such as obesity, type 2 diabetes mellitus, type 1 
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic 
fatty liver disease (NAFLD), nonalcoholic steatohepatitis 
(NASH), insulin resistance, hyperinsulinemia, glucose intol 
erance, hyperglycemia, metabolic syndrome, acute myocar 
dial infarction, hypertension, cardiovascular disease, athero 
Sclerosis, peripheral arterial disease, stroke, heart failure, 
coronary heart disease, kidney disease, diabetic complica 
tions, neuropathy, gastroparesis, disorders associated with 
inactivating mutations in the insulin receptor, and other meta 
bolic disorders, comprising administering to said patient in 
need of such treatment a therapeutically effective amount of 
one or more proteins of the invention or a pharmaceutical 
composition thereof. 
0022. The invention also provides pharmaceutical compo 
sitions comprising the fusion proteins of the invention dis 
closed herein and a pharmaceutically acceptable formulation 
agent. Such pharmaceutical compositions can be used in a 
method for treating a metabolic disorder, and the method 
comprises administering to a human patient in need thereof a 
pharmaceutical composition of the invention. Non-limiting 
examples of metabolic disorders that can be treated include 
type 1 and type 2 diabetes mellitus and obesity. 
0023 These and other aspects of the invention will be 
elucidated in the following detailed description of the inven 
tion. 
BRIEF DESCRIPTION OF THE DRAWINGS 
(0024 FIGS. 1A-1D show V188 has improved efficacy in 
the ob/ob diabetic mouse model over V76. V188 shows supe 
rior results when administered at 1 milligram per kilogram 
(mpk), compared to the 5 milligram per kilogram at which 
V76 was administered. FIG. 1A shows fed plasma glucose as 
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a readout (circles represent vehicle (PBS phosphate buff 
ered saline), squares represent V76 at 5 mpk, and triangles 
representV188 at 1 mpk. FIG.1B shows fed plasma insulinas 
a readout (from left to right: vehicle, V76 at 5 mpk, and V188 
at 1 mpk). FIG. 1C shows body weight as a readout (from left 
to right: vehicle, V76 at 5 mpk, and V188 at 1 mpk). FIG. 1D 
shows liver lipid content as a readout (from left to right: 
vehicle, V76 at 5 mpk, and V188 at 1 mpk). 
0025 FIGS. 2A-2D show V101 has improved efficacy in 
the ob/ob diabetic mouse model over V76. V101 shows supe 
rior results when administered at 1 milligram per kilogram 
(mpk), compared to the 5 milligram per kilogram at which 
V76 was administered. FIG. 2A shows fed plasma glucose as 
a readout (circles represent vehicle (PBS phosphate buff 
ered saline), squares represent V76 at 5 mpk, and triangles 
representV101 at 1 mpk. FIG.2B shows fed plasma insulinas 
a readout (from left to right: vehicle, V76 at 5 mpk, and V101 
at 1 mpk). FIG. 2C shows body weight as a readout (from left 
to right: vehicle, V76 at 5 mpk, and V101 at 1 mpk). FIG. 2D 
shows liver lipid content as a readout (from left to right: 
vehicle, V76 at 5 mpk, and V101 at 1 mpk). 
0026 FIGS. 3A-3D show V103 has improved efficacy in 
the ob/ob diabetic mouse model over V76. V103 shows supe 
rior results when administered at 1 milligram per kilogram 
(mpk), compared to the 5 milligram per kilogram at which 
V76 was administered. FIG. 3A shows fed plasma glucose as 
a readout (circles represent vehicle (PBS phosphate buff 
ered saline), squares represent V76 at 5 mpk, and triangles 
representV103 at 1 mpk. FIG.3B shows fed plasma insulinas 
a readout (from left to right: vehicle, V76 at 5 mpk, and V103 
at 1 mpk). FIG. 3C shows body weight as a readout (from left 
to right: vehicle, V76 at 5 mpk, and V103 at 1 mpk). 
0027 FIG. 3D shows liver lipid content as a readout (from 
left to right: vehicle, V76 at 5 mpk, and V103 at 1 mpk). 
0028 FIGS. 4A-4D demonstrate the Superior pharmaco 
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fusion proteins of the invention over FGF21 fusion proteins in 
the art. FIG. 4A shows the plasma concentrations of fusion 
proteins of the invention in PCT Publication WO10/129,600 
described as Fc-L(15)-FGF21 (L98R, P171G) and Fc-L(15)- 
FGF21 (L98R, P171G, A180E), following the IV injection of 
said fusion in mice. FIG. 4B shows pharmacokinetic proper 
ties of the fusion proteins of the invention (V101, V103 & 
V188) after a single IV dose in the mouse as assayed by 
anti-Fc-ELISA compared with pharmacokinetic data gener 
ated in the mouse for V76 in a previous study using an anti 
FGF21 antibody ELISA. FIG. 4C shows a spot check of the 
fusion proteins of the invention in an anti-FGF21 Western 
blot, consistent with anti-Fc-ELISA data at 120 hours and 15 
days. The samples in the blot are as follows: A represents 
V101, B represents V103, and C represents V188. Control is 
V101 and serum. FIG. 4D demonstrates the significantly 
increased thermodynamic stability of the fusion proteins of 
the invention compared to V76. From top to bottom, the figure 
represents V101, V103, and V188, all of which have 
improved melting temperatures (T,) compared to V76 
(T<50° C. (not shown)) and wild-type FGF21 (T46.5 
C+0.3 (not shown)). 
DETAILED DESCRIPTION OF THE INVENTION 
0029. The fusion proteins of the present invention repre 
sent modified versions of the full length, wild-type FGF21 
polypeptide, as known in the art. FGF21 wild-type sequence 
will serve as a reference sequence (SEQ ID NO:1), for 
instance, when comparisons between the FGF21 wild-type 
sequence and the protein variants are necessary. The FGF21 
wild-type sequence has NCBI reference sequence number 
NP 061986.1, and can be found in such issued patents as, 
e.g., U.S. Pat. No. 6,716,626B1, assigned to Chiron Corpo 
ration (SEQID NO:1). 
Thir Glu Wall 
15 
His Ser Ser Asp Glu 
5 
Gly Phe Gly Lieu. Trp 
Ala 
25 
Glin Ala Pro Ile Pro Gly Lieu Lleu Lieu. His Gly 
Glin Phe 
4 O 





Glin Thr Glu Ala His Lieu. Glu Ile 
6 O 
Asp Asp Arg 







Lieu Lys Pro Gly Ile Glin Lieu. Gly Val 
95 
Arg Phe Lieu. Glin Pro Cys Arg 
105 
Asp Gly Lel 
11 O 
Tyr Gly 
Phe Glu Ala 
12 O 
Asp Pro Ser Phe Cell Lieu. Luell 
Wall Glin Glu Ala His Pro Leu 
14 O 
Asn Tyr Ser Lel 
135 






Phe Pro Glu 
17s 
Leul Pro Pro 
17O 
Leul Pro Leu Pro 
1.65 
Gly Lel 
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Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
18O 185 19 O 
Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
195 2OO 2O5 
Ser 
209 
0030 The corresponding mRNA sequence coding for the 
full-length FGF21 polypeptide (NCBI reference sequence 
number NM 019113.2) is shown below (SEQ ID NO:2) 
Ctgtcagctg aggat.ccagc cgaaagagga gccaggcact caggccacct gagt ct actic 
61 acctggacaa citggaatctg goaccaattic taaac cactic agctitct cog agct cacacc 
121 ccggagat.ca cct gaggacc cagc cattg atggacticgg acgaga.ccgg gttctgagcac 
181 tdaggactgt gggtttctgt gctggctggit Cttctgctgg gagcctgcca gg cacacccC 
241 atcc.ctgact c cagt cct ct cotgcaattic gggggccaag to cqgcagog gtacct citac 
301 acagatgatg cccagcagac agaagcc cac ctggagat.ca gggaggatgg gacggtgggg 
361 ggcgctgctg accagagcCC cqaaagt ct c ctgcagctga aagccttgaa gC cgggagtt 
421 attcaaatct tdgagt cala gacat coagg tt CCtgtgcc agcggccaga tiggggg cctg 
481 tatggat.cgc. tcc actittga CCCtgaggcc ticagottcc gggagctgct tcttgaggac 
541 ggatacaatgtttaccagtic cqaagcc cac ggcct cocgc tigcacct gcc agggaacaag 
601 tocccacacc gggaccctgc accc.cgagga ccagotcgct tcct gcc act accaggcctg 
661 ccc.ccc.gcac toccggagcc acccggaatc ct gg.ccc.ccc agc.ccc.ccga tigtgggcticc 
721 toggaccCt c taggatggit gggacct tcc cagggcc.gala gCCC cagct a cqct tcctga 
781 agccagaggc tigtttact at gacat ct cot ctittattitat taggittattt at cittattta 
841 ttitttittatt tttct tactt gagataataa agagttccag aggagaaaaa aaaaaaaaaa 
90 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa. 
0031. The mature FGF21 sequence lacks a leader post-translational modifications understood by those with 
sequence and may also include other modifications of a 
polypeptide Such as proteolytic processing of the amino ter 
minus (with or without a leader sequence) and/or the carboxyl 
terminus, cleavage of a smaller polypeptide from a larger 















Leu Tyr Gly 
skill in the art. A representative example of a mature FGF21 
sequence has the following sequence (SEQID NO:3, which 
represents amino acid positions 29-209 of full length FGF21 
protein sequence (NCBI reference sequence number 
NP 061986.1)): 
Glin Phe Glin 
15 
Pro Asp Ser Ser Pro Lieu. Lieu. Wall Gly Gly 
Thir Ala Glin Glin. Thir Glu 
3 O 




Wall Ala Ala 
45 
Arg Glu Asp Gly Gly Gly Asp Glin Ser 




Lieu. Luell Lys Gly 
Wall Thir 
70 
Ser Arg Phe Lieu. Cys Glin Pro Arg Asp Gly 
8O 




Ser Lieu. His 
85 
Asp Arg 
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Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu 
1OO 105 11 O 
Gly Lieu Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg 
115 12 O 125 
Ala Pro Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu. 
13 O 135 14 O 
Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro 
145 150 155 
Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly 
1.65 17O 
Pro Ser Tyr Ala Ser 
18O 
0032. The corresponding cDNA sequence coding for the 
mature FGF21 polypeptide (SEQ ID NO:3) is shown below 
(SEQ ID NO:4): 








Caccc catcc ctgactic cag to Ctctic ctg caatt.cgggg gccaagt ccg gCagcggtac 
61 Ctctacacag atgatgcc.ca gcagacagaa gC ccacctgg agat Caggga ggatgggacg 
121 gtggggggcg Ctgctgacca gagcc.ccgala agtict Cotgc agctgaaagc Cttgaa.gc.cg 
181 ggagittatt C aaatcttggg agt caagaca to Caggttcc titgc.ca.gcg gccagatggg 
240 gocct gtatg gatcgct coa ctittgaccct gaggcctgca gct tccggga gotgctitctt 
301 gaggacggat acaatgttta CcagtCc gala gCC CacggCC to CC gCtgca CCtgcCaggg 
360 aacaagt ccc cacac cqgga ccctgcaccc cdaggaccag ct cqct tcct gccactacca 
421 ggcctgccCC cc.gcact coc ggagccaccc ggaatcc tig cc ccc.ca.gcc ccc.cgatgtg 
481 ggctic ct cqg accct ctgag catggtggga cct tcc.cagg gcc.gaag.ccc cagctacgct 
541 toctda 
0033. The fusion proteins of the invention may comprise 
protein variants or mutants of the wild-type proteins listed 
herein, e.g., FGF21 variants. As used herein, the terms “pro 
tein variant,” “human variant,” “polypeptide or protein vari 
ant.” “variant.” “mutant, as well as any like terms or specific 
versions thereof (e.g., “FGF21 protein variant,” “variant.” 
“FGF21 mutant, etc.) define protein or polypeptide 
sequences that comprise modifications, truncations, other 
variants of naturally occurring (i.e., wild-type) protein or 
polypeptide counterparts or corresponding native sequences. 
“Variant FGF21 or “FGF21 mutant, for instance, is 
described relative to the wild-type (i.e., naturally occurring) 
FGF21 protein as described herein. 
0034 Representative fusion protein sequences of the 
invention are listed in Table 1. The descriptions of said 
fusions include the FGF21 variant and, where applicable, a 
linker. The changes or substitutions employed by the FGF21 
variant are numbered and described relative to wild-type 
FGF21. By way of example, “Variant 101 (V101)” (SEQ ID 
NO:10) is an Fc-FGF21 fusion with a two amino acid linker 
and the following substitutions made relative to wild type 
FGF21: Q55C, A109T, G148C, K150R, P158S, P174L, 
S195A, P199G, G202A. 
TABLE 1. 
FGF21 Variant Fc fusion proteins 
SEQ 
ID 










APEAAGGPSV FLFPPKPKDT Full Length N-term Fo-Fusion 
CVVVDVSHED PEVKFNWYWD with 2 AA Linker (GS) and 
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TABLE 1 - continued 
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FGF21 Variant Fc fusion proteins 
SEQ 
ID 
NO: Sequence Namek 
SPHRDPASRG PARFLPLPGL PPALPEPPGI 
LAPOPPDWGS SDPLAMWGGS QARSPSYAS 
13 DKTHTCPPCP APEAAGGPSV FLFPPKPKDT Variant H2O4 = V101 with 15 AA 
LMISRTPEVT CVVVDVSHED PEVKFNWYWD Linker (GGGGS x 3) between Fc 
GWEVHNAKTK PREEOYNSTY RVVSVLTVLH and FGF21 = (Q55C, A109T 
ODWLNGKEYK CKVSNKALPA PIEKTISKAK G148C K15 OR P158S, S195A, 
GOPREPOVYT LPPSREEMTK NOVSLTCLVK P199G G2O2A) 
GFYPSDIAVE WESNGOPENN YKTTPPVLDS 
DGSFFLYSKL TVDKSRWOOG NWFSCSVMHE 
ALHNHYTOKS LSLSPGKGGG GSGGGGSGGG 
GSDSSPLLQF GGQVRQRYLY TDDACQTEAH 
LEIREDGTWG GAADQSPESL LOLKALKPGV 
IOILGVKTSR FLCORPDGTL YGSLHFDPEA 
CSFRELLLED GYNWYOSEAH GLPLHLPCNR 
SPHRDPASRG PARFLPLPGL PPALPEPPGI 
LAPOPPDWGS SDPLAMWGGS QARSPSYAS 
- Note 
that the FGF21 wild-type sequence in this table refers to NCBI reference sequence 
number NP O61986. 1 (SEQ ID NO: 1) unless otherwise specified. 
All mutations in the FGF21 moiety and corresponding amino 
acid numbering of said mutations refers back to (SEQ ID 
NO: 1) not to the full-length sequences in this table which may 
also include Fc and linker regions. 
0035. The variants or mutants used in the fusion proteins 
of the invention, e.g., variants of wild-type FGF21, feature at 
least one Substituted, added, and/or removed amino acid rela 
tive to the wild-type protein. Additionally, the variants may 
include N- and/or C-terminal truncations relative to the wild 
type proteins. Generally speaking, a variant possesses some 
modified property, structural or functional, of the wild-type 
protein. For example, the variant may have enhanced or 
improved physical stability in concentrated solutions (e.g., 
less hydrophobic mediated aggregation), enhanced or 
improved plasma stability when incubated with blood plasma 
or enhanced or improved bioactivity while maintaining a 
favorable bioactivity profile. 
0036. Acceptable amino acid substitutions and modifica 
tions which constitute differences between the portions of the 
fusion proteins of the invention and their wild-type compara 
torproteins include, but are not limited to, one or more amino 
acid Substitutions, including Substitutions with non-naturally 
occurring amino acid analogs, and truncations. Thus, the 
fusion proteins of the invention (e.g., the fusion proteins of 
the invention) include, but are not limited to, site-directed 
mutants, truncated polypeptides, proteolysis-resistant 
mutants, aggregation-reducing mutants, combination 
mutants, and fusion proteins, as described herein. 
0037. One skilled in the art of expression of proteins will 
recognize that methionine or methionine-arginine sequence 
can be introduced at the N-terminus of any of the fusion 
proteins of the invention, for expression in E. coli, and are 
contemplated within the context of this invention. 
0038. The fusion proteins of the invention may possess 
increased compatibility with pharmaceutical preservatives 
(e.g., m-cresol, phenol, benzyl alcohol), thus enabling the 
preparation of a preserved pharmaceutical formulation that 
maintains the physiochemical properties and biological activ 
ity of the protein during storage. Accordingly, variants with 
enhanced pharmaceutical stability relative to wild-type, have 
improved physical stability in concentrated solutions under 
both physiological and preserved pharmaceutical formula 
tion conditions, while maintaining biological potency. By 
way of non-limiting example, the fusion proteins of the inven 
tion may be more resistant to proteolysis and enzymatic deg 
radation; may have improved Stability; and may be less likely 
to aggregate, than their wild-type counterparts or correspond 
ing native sequence. As used herein, these terms are not 
mutually exclusive or limiting, it being entirely possible that 
a given variant has one or more modified properties of the 
wild-type protein. 
0039. The invention also encompasses nucleic acid mol 
ecules encoding the fusion proteins of the invention, compris 
ing, for example, an FGF21 amino acid sequence that is at 
least about 95% identical to the amino acid sequence of SEQ 
ID NO:3, but wherein specific residues conferring a desirable 
property to the FGF21 protein variant, e.g., improved potency 
to FGF21-receptors, proteolysis-resistance, increased half 
life or aggregation-reducing properties and combinations 
thereof have not been further modified. In other words, with 
the exception of residues in the FGF21 mutant sequence that 
have been modified in order to confer proteolysis-resistance, 
aggregation-reducing, or other properties, about 5% (alter 
nately 4%, alternately 3%, alternately 2%, alternately 1%) of 
all other amino acid residues in the FGF21 mutant sequence 
can be modified. Such FGF21 mutants possess at least one 
activity of the wild-type FGF21 polypeptide. 
0040. The invention also encompasses a nucleic acid mol 
ecule comprising a nucleotide sequence that is at least about 
85%, identical, and more preferably, at least about 90 to 95% 
identical to the nucleotide sequence of SEQID NO:2 or SEQ 
ID NO:4, but wherein the nucleotides encoding amino acid 
residues conferring the encoded protein's proteolysis-resis 
tance, aggregation-reducing or other properties have not been 
further modified. In other words, with the exception of nucle 
otides that encode residues in the FGF21 mutant sequences 
that have been modified in order to confer proteolysis-resis 
tance, aggregation-reducing, or other properties, about 15%, 
and more preferably about 10 to 5% of all other nucleotides in 
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the mutant sequence can be modified. Such nucleic acid mol 
ecules encode proteins possessing at least one activity of their 
wild-type counterparts. 
0041) Provided herein are methods used to generate the 
fusion proteins of the invention, wherein such methods 
involve site-specific modification and non-site-specific modi 
fication of the wild-type versions of the proteins (e.g., the 
FGF21 wild-type protein as described herein), e.g., trunca 
tions of the wild-type proteins, and the site-specific incorpo 
ration of amino acids at positions of interest within the wild 
type proteins. Said modifications enhance the biological 
properties of the fusion proteins of the invention relative to 
the wild-type proteins, as well as, in some cases, serving as 
points of attachment for, e.g., labels and protein half-life 
extension agents, and for purposes of affixing said variants to 
the surface of a solid support. Related embodiments of the 
invention are methods of producing cells capable of produc 
ing said Fusion Proteins of the invention, and of producing 
vectors containing DNA encoding said variants. 
0042. In certain embodiments, such modifications, e.g., 
site-specific modifications, are used to attach conjugates, e.g., 
PEG groups to proteins, polypeptides, and/or peptides of the 
invention, for purposes of, e.g., extending half-life or other 
wise improving the biological properties of said proteins, 
polypeptides, and/or peptides. Said techniques are described 
further herein. 
0043. In other embodiments, such modifications, e.g., 
site-specific modifications, are used to attach other polymers, 
small molecules and recombinant protein sequences that 
extend half-life of the protein of the invention. One such 
embodiment includes the attachment offatty acids or specific 
albuminbinding compounds to proteins, polypeptides, and/or 
peptides. In other embodiments, the modifications are made 
at a particular amino acid type and may be attached at one or 
more sites on the protein. 
0044. In other embodiments, such modifications, e.g., 
site-specific modifications, are used as means of attachment 
for the production of wild-type and/or variant multimers, e.g., 
dimers (homodimers or heterodimers) or trimers or tetramers. 
These multimeric protein molecules may additionally have 
groups such as PEG, Sugars, and/or PEG-cholesterol conju 
gates attached or be fused either amino-terminally or car 
boxy-terminally to other proteins such as Fc. Human Serum 
Albumin (HSA), etc. 
0045. In other embodiments, such site-specific modifica 
tions are used to produce proteins, polypeptides and/or pep 
tides wherein the position of the site-specifically incorporated 
pyrrolysine or pyrrolysine analogue or non-naturally occur 
ring amino acids (para-acetyl-Phe, para-azido-Phe) allows 
for controlled orientation and attachment of Such proteins, 
polypeptides and/or peptides onto a Surface of a solid Support 
or to have groups such as PEG, sugars and/or PEG-choles 
terol conjugates attached. 
0046. In other embodiments, such site-specific modifica 
tions are used to site-specifically cross-link proteins, 
polypeptides and/or peptides thereby forming hetero-oligo 
mers including, but not limited to, heterodimers and heterot 
rimers. In other embodiments, such site-specific modifica 
tions are used to site-specifically cross-link proteins, 
polypeptides and/or peptides thereby forming protein-protein 
conjugates, protein-polypeptide conjugates, protein-peptide 
conjugates, polypeptide-polypeptide conjugates, polypep 
tide-peptide conjugates or peptide-peptide conjugates. In 
other embodiments, a site specific modification may include 
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a branching point to allow more than one type of molecule to 
be attached at a single site of a protein, polypeptide or peptide. 
0047. In other embodiments, the modifications listed 
herein can be done in a non-site-specific manner and result in 
protein-protein conjugates, protein-polypeptide conjugates, 
protein-peptide conjugates, polypeptide-polypeptide conju 
gates, polypeptide-peptide conjugates or peptide-peptide 
conjugates of the invention. 
DEFINITIONS 
0048 Various definitions are used throughout this docu 
ment. Most words have the meaning that would be attributed 
to those words by one skilled in the art. Words specifically 
defined either below or elsewhere in this document have the 
meaning provided in the context of the present invention as a 
whole and as are typically understood by those skilled in the 
art. 
0049. As used herein, the term “FGF21 refers to a mem 
ber of the fibroblast growth factor (FGF) protein family. An 
amino acid sequence of FGF21 (GenBank Accession No. 
NP 061986.1) is set forth as SEQID NO:1, the correspond 
ing polynucleotide sequence of which is set forth as SEQID 
NO:2 (NCBI reference sequence number NM 019113.2). 
“FGF21 variant,” “FGF21 mutant and similar terms 
describe modified version of the FGF21 protein, e.g., with 
constituent amino acid residues deleted, added, modified, or 
substituted. 
0050. As used herein, the term “FGF21 receptor” refers to 
a receptor for FGF21 (Kharitonenkov, A. etal. (2008) Journal 
of Cellular Physiology 215:1-7: Kurosu, Het al. (2007) JBC 
282:26687-26695; Ogawa, Yet al. (2007) PNAS 104:7432 
7437). 
0051. The term “FGF21 polypeptide” refers to a naturally 
occurring polypeptide expressed in humans. For purposes of 
this disclosure, the term “FGF21 polypeptide' can be used 
interchangeably to refer to any full-length FGF21 polypep 
tide, e.g., SEQ ID NO:1, which consists of 209 amino acid 
residues and which is encoded by the nucleotide sequence of 
SEQ ID NO:2; any mature form of the polypeptide, which 
consists of 181 amino acid residues, and in which the 28 
amino acid residues at the amino-terminal end of the full 
length FGF21 polypeptide (i.e., which constitute the signal 
peptide) have been removed. 
0052 “Variant 76,” as used herein, is an FGF21 protein 
variant, featuring a 40 kDa branched PEG linked through 
Cys 154, and eight point mutations relative to the 177 amino 
acid wild-type protein. Synthesis of the variant is described in 
greater detail herein, and the protein sequence is represented 
in Table 1 and SEQID NO:9. 
0053. The term “isolated nucleic acid molecule' refers to 
a nucleic acid molecule of the present invention that (1) has 
been separated from at least about 50 percent of proteins, 
lipids, carbohydrates, or other materials with which it is natu 
rally found when total nucleic acid is isolated from the source 
cells, (2) is not linked to all or a portion of a polynucleotide to 
which the "isolated nucleic acid molecule' is linked in nature, 
(3) is operably linked to a polynucleotide which it is not 
linked to in nature, or (4) does not occur in nature as part of a 
larger polynucleotide sequence. Preferably, the isolated 
nucleic acid molecule of the present invention is substantially 
free from any other contaminating nucleic acid molecules or 
other contaminants that are found in its natural environment 
that would interfere with its use in polypeptide production or 
its therapeutic, diagnostic, prophylactic or research use. 
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0054) The term “vector” is used to refer to any molecule 
(e.g., nucleic acid, plasmid, or virus) used to transfer coding 
information to a host cell. 
0055. The term “expression vector” refers to a vector that 
is Suitable for transformation of a host cell and contains 
nucleic acid sequences that direct and/or control the expres 
sion of inserted heterologous nucleic acid sequences. Expres 
sion includes, but is not limited to, processes such as tran 
Scription, translation, and RNA splicing, if introns are 
present. 
0056. The term “operably linked' is used herein to refer to 
an arrangement of flanking sequences wherein the flanking 
sequences so described are configured or assembled so as to 
perform their usual function. Elements of fusions proteins 
may be operably linked to one another so as to allow the 
fusion protein to function as if it were a naturally occurring, 
endogenous protein, and/or to combine disparate elements of 
said fusion proteins in a synergistic fashion. 
0057. On a nucleotide level, a flanking sequence operably 
linked to a coding sequence may be capable of effecting the 
replication, transcription and/or translation of the coding 
sequence. For example, a coding sequence is operably linked 
to a promoter when the promoter is capable of directing 
transcription of that coding sequence. A flanking sequence 
need not be contiguous with the coding sequence, so long as 
it functions correctly. Thus, for example, intervening untrans 
lated yet transcribed sequences can be present between a 
promoter sequence and the coding sequence and the promoter 
sequence can still be considered "operably linked to the 
coding sequence. 
0058. The term “host cell is used to refer to a cell which 
has been transformed, or is capable of being transformed with 
a nucleic acid sequence and then of expressing a selected gene 
of interest. The term includes the progeny of the parent cell, 
whether or not the progeny is identical in morphology or in 
genetic make-up to the original parent, so long as the selected 
gene is present. 
0059. The term “amino acid,” as used herein, refers to 
naturally occurring amino acids, unnatural amino acids, 
amino acid analogues and amino acid mimetics that function 
in a manner similar to the naturally occurring amino acids, all 
in their D and L stereoisomers if their structure allows such 
stereoisomeric forms. Amino acids are referred to herein by 
either their name, their commonly known three letter symbols 
or by the one-letter symbols recommended by the IUPAC 
IUB Biochemical Nomenclature Commission. 
0060. The term “naturally occurring” when used in con 
nection with biological materials such as nucleic acid mol 
ecules, polypeptides, host cells, and the like, refers to mate 
rials which are found in nature and are not manipulated by 
man. Similarly, “non-naturally occurring as used herein 
refers to a material that is not found in nature or that has been 
structurally modified or synthesized by man. When used in 
connection with nucleotides, the term “naturally occurring 
refers to the bases adenine (A), cytosine (C), guanine (G), 
thymine (T), and uracil (U). When used in connection with 
amino acids, the term “naturally occurring refers to the 20 
conventional amino acids (i.e., alanine (A), cysteine (C), 
aspartic acid (D), glutamic acid (E), phenylalanine (F), gly 
cine (G), histidine (H), isoleucine (I), lysine (K), leucine (L), 
methionine (M), asparagine (N), proline (P), glutamine (Q). 
arginine (R), serine (S), threonine (T), Valine (V), tryptophan 
(W), and tyrosine (Y)), as well as selenocysteine, pyrrolysine 
(Pyl, or O), and pyrroline-carboxy-lysine (Pcl, or Z). 
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0061 Pyrrolysine (Pyl) is an amino acid naturally found 
within methylamine methyltransferases of methanogenic 
archaea of the family Methanosarcina. Pyrrolysine is alysine 
analogue co-translationally incorporated at in-frame UAG 
codons in the respective mRNA, and it is considered the 22nd 
natural amino acid. 
0062. As described at least in PCT patent publication 
WO2010/48582 (applicant IRM, LLC), attempts to biosyn 
thesize pyrrolysine (Pyl) in E. coli resulted in the formation of 
a "demethylated pyrrolysine.” referred to herein as pyrroline 
carboxy-lysine, or Pcl. “Pel,” as used herein, refers to either 
Pcl-A or Pcl-B. 
0063. The terms “non-natural amino acid' and “unnatural 
amino acid, as used herein, are interchangeably intended to 
representamino acid structures that cannot be generated bio 
synthetically in any organism using unmodified or modified 
genes from any organism, whether the same or different. The 
terms refer to an amino acid residue that is not present in the 
naturally occurring (wild-type) FGF21 protein sequence or 
the sequences of the present invention. These include, but are 
not limited to, modified amino acids and/or amino acid ana 
logues that are not one of the 20 naturally occurring amino 
acids, selenocysteine, pyrrolysine (Pyl), or pyrroline-car 
boxy-lysine (Pcl, e.g., as described in PCT patent publication 
WO2010/48582). Such non-natural amino acid residues can 
be introduced by Substitution of naturally occurring amino 
acids, and/or by insertion of non-natural amino acids into the 
naturally occurring (wild-type) FGF21 protein sequence or 
the sequences of the invention. The non-natural amino acid 
residue also can be incorporated Such that a desired function 
ality is imparted to the FGF21 molecule, for example, the 
ability to link a functional moiety (e.g., PEG). When used in 
connection with amino acids, the symbol “U” shall mean 
“non-natural amino acid and "unnatural amino acid as used 
herein. 
0064. In addition, it is understood that such “unnatural 
amino acids’ require a modified tRNA and a modified tRNA 
synthetase (RS) for incorporation into a protein. These 
“selected orthogonal tRNA/RS pairs are generated by a 
selection process as developed by Schultz et al. or by random 
or targeted mutation. As way of example, pyrroline-carboxy 
lysine is a “natural amino acid as it is generated biosyntheti 
cally by genes transferred from one organism into the host 
cells and as it is incorporated into proteins by using natural 
tRNA and tRNA synthetase genes, while p-aminophenylala 
nine (See, Generation of a bacterium with a 21 amino acid 
genetic code, Mehl RA. Anderson J C, Santoro SV V. Wang 
L., Martin AB, King DS, Horn DM, Schultz PG. JAm Chem. 
Soc. 2003 Jan. 29; 125(4):935-9) is an “unnatural amino 
acid because, although generated biosynthetically, it is 
incorporated into proteins by a “selected orthogonal tRNA/ 
tRNA synthetase pair. 
0065 Modified encoded amino acids include, but are not 
limited to, hydroxyproline, Y-carboxyglutamate, O-phospho 
serine, aZetidinecarboxylic acid, 2-aminoadipic acid, 3-ami 
noadipic acid, beta-alanine, aminopropionic acid, 2-ami 
nobutyric acid, 4-aminobutyric acid, 6-aminocaproic acid, 
2-aminoheptanoic acid, 2-aminoisobutyric acid, 3-ami 
noisobutyric acid, 2-aminopimelic acid, tertiary-butylgly 
cine, 2,4-diaminoisobutyric acid, desmosine, 2,2'-diami 
nopimelic acid, 2,3-diaminoproprionic acid, N-ethylglycine, 
N-methylglycine, N-ethylasparagine, homoproline, 
hydroxylysine, allo-hydroxylysine, 3-hydroxyproline, 4-hy 
droxyproline, isodesmosine, allo-isoleucine, N-methylala 
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nine, N-methylglycine, N-methylisoleucine, N-methylpen 
tylglycine, N-methylvaline, naphthalanine, norvaline, 
norleucine, ornithine, pentylglycine, pipecolic acid and thio 
proline. The term “amino acid also includes naturally occur 
ring amino acids that are metabolites in certain organisms but 
are not encoded by the genetic code for incorporation into 
proteins. Such amino acids include, but are not limited to, 
ornithine, D-ornithine, and D-arginine. 
0066. The term “amino acid analogue.” as used herein, 
refers to compounds that have the same basic chemical struc 
ture as a naturally occurring amino acid, by way of example 
only, an O-carbon that is bound to a hydrogen, a carboxyl 
group, an amino group, and an R group. Amino acid ana 
logues include the natural and unnatural amino acids which 
are chemically blocked, reversibly or irreversibly, or their 
C-terminal carboxy group, their N-terminal amino group and/ 
or their side-chain functional groups are chemically modi 
fied. Such analogues include, but are not limited to, methion 
ine sulfoxide, methionine sulfone, S-(carboxymethyl)- 
cysteine, S-(carboxymethyl)-cysteine Sulfoxide, 
S-(carboxymethyl)-cysteine Sulfone, aspartic acid-(beta-me 
thyl ester), N-ethylglycine, alanine carboxamide, 
homoserine, norleucine, and methionine methyl sulfonium. 
0067. The term “amino acid mimetics,” as used herein, 
refers to chemical compounds that have a structure that is 
different from the general chemical structure of an amino 
acid, but functions in a manner similar to a naturally occurring 
amino acid. 
0068. The term “biologically active variant” refers to any 
polypeptide variant used in the fusion proteins of the inven 
tion, e.g., as a constituent protein of the fusions, that pos 
sesses an activity of its wild-type (e.g., naturally-occurring) 
protein or polypeptide counterpart, Such as the ability to 
modulate blood glucose, HbAlc, insulin, triglyceride, or cho 
lesterol levels; increase pancreatic function; reduce lipid lev 
els in liver, reduce body weight; and to improve glucose 
tolerance, energy expenditure, or insulin sensitivity, regard 
less of the type or number of modifications that have been 
introduced into the polypeptide variant. Polypeptide variants 
possessing a somewhat decreased level of activity relative to 
their wild-type versions can nonetheless be considered to be 
biologically active polypeptide variants. A non-limiting rep 
resentative example of a biologically active polypeptide vari 
ant of the invention is an FGF21 variant, which is modified 
after, and possesses similar or enhanced biological properties 
relative to, wild-type FGF21. 
0069. The terms “effective amount” and “therapeutically 
effective amount each refer to the amount of a fusion protein 
of the invention used to support an observable level of one or 
more biological activities of the wild-type polypeptide or 
protein counterparts, such as the ability to lower blood glu 
cose, insulin, triglyceride or cholesterol levels; reduce liver 
triglyceride or lipid levels; reduce body weight; or improve 
glucose tolerance, energy expenditure, or insulin sensitivity. 
For example, a “therapeutically-effective amount’ adminis 
tered to a patient exhibiting, Suffering, or prone to Suffer from 
FGF21-associated disorders (such as type 1 or type 2 diabetes 
mellitus, obesity, or metabolic syndrome), is such an amount 
which induces, ameliorates or otherwise causes an improve 
ment in the pathological symptoms, disease progression, 
physiological conditions associated with or resistance to Suc 
cumbing to the afore mentioned disorders. For the purposes 
of the present invention a “subject' or “patient' is preferably 
a human, but can also be an animal, more specifically, a 
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companion animal (e.g., dogs, cats, and the like), farm ani 
mals (e.g., cows, sheep, pigs, horses, and the like) and labo 
ratory animals (e.g., rats, mice, guinea pigs, and the like). 
0070 The term “pharmaceutically acceptable carrier' or 
“physiologically acceptable carrier as used herein refers to 
one or more formulation materials suitable for accomplishing 
or enhancing the delivery of a fusion protein of the invention. 
0071. The term “antigen” refers to a molecule or a portion 
of a molecule that is capable of being bound by an antibody, 
and additionally that is capable of being used in an animal to 
produce antibodies that are capable of binding to an epitope of 
that antigen. An antigen may have one or more epitopes. 
0072 The term “native Fc refers to molecule or sequence 
comprising the sequence of a non-antigen-binding fragment 
resulting from digestion of whole antibody or produced by 
other means, whether in monomeric or multimeric form, and 
can contain the hinge region. The original immunoglobulin 
Source of the native Fc is preferably of human origin and can 
be any of the immunoglobulins, although IgG1 and IgG2 are 
preferred. Native Fc molecules are made up of monomeric 
polypeptides that can be linked into dimeric or multimeric 
forms by covalent (i.e., disulfide bonds) and non-covalent 
association. The number of intermolecular disulfide bonds 
between monomeric Subunits of native Fc molecules ranges 
from 1 to 4 depending on class (e.g., IgG, IgA, and IgE) or 
Subclass (e.g., IgG1, IgG2, IgG3, IgA1, and IgGA2). One 
example of a native Fc is a disulfide-bonded dimer resulting 
from papain digestion of an IgG (see Ellison et al., 1982, 
Nucleic Acids Res. 10:4071-9). The term “native Fc” as used 
herein is generic to the monomeric, dimeric, and multimeric 
forms. 
0073. The term “Fc variant refers to a molecule or 
sequence that is modified from a native Fc but still comprises 
a binding site for the Salvage receptor, FcRn (neonatal Fc 
receptor). International Publication Nos. WO97/34631 and 
WO 96/32478 describe exemplary Fc variants, as well as 
interaction with the Salvage receptor, and are hereby incor 
porated by reference. Thus, the term “Fc variant can com 
prise a molecule or sequence that is humanized from a non 
human native Fc. Furthermore, a native Fc comprises regions 
that can be removed because they provide structural features 
or biological activity that are not required for the fusion 
molecules of the fusion proteins of the invention. Thus, the 
term "Fc variant comprises a molecule or sequence that 
lacks one or more native Fc sites or residues, or in which one 
or more Fc sites or residues has be modified, that affect or are 
involved in: (1) disulfide bond formation, (2) incompatibility 
with a selected host cell, (3) N-terminal heterogeneity upon 
expression in a selected host cell, (4) glycosylation, (5) inter 
action with complement, (6) binding to an Fc receptor other 
than a salvage receptor, or (7) antibody-dependent cellular 
cytotoxicity (ADCC). Fc variants are described in further 
detail hereinafter. 
0074 The term “Fc domain encompasses native Fc and 
Fc variants and sequences as defined above. As with Fc vari 
ants and native Fc molecules, the term "Fc domain includes 
molecules in monomeric or multimeric form, whether 
digested from whole antibody or produced by other means. In 
Some embodiments of the present invention, an Fc domain 
can be fused to FGF21 or a FGF21 mutant (including a 
truncated form of FGF21 or a FGF21 mutant) via, for 
example, a covalent bond between the Fc domain and the 
FGF21 sequence. Such fusion proteins can form multimers 
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via the association of the Fc domains and both these fusion 
proteins and their multimers are an aspect of the present 
invention. 
0075. The term “modified Fc fragment”, as used herein, 
shall mean an Fc fragment of an antibody comprising a modi 
fied sequence. The Fc fragment is a portion of an antibody 
comprising the CH2, CH3 and part of the hinge region. The 
modified Fc fragment can be derived from, for example, 
IgG1, IgG2, IgG3, or IgG4. FcLALA is a modified Fc frag 
ment with a LALA mutation (L234A, L235A), which triggers 
ADCC with lowered efficiency, and binds and activates 
human complement weakly. Hessell et al. 2007 Nature 449: 
101-104. Additional modifications to the Fc fragment are 
described in, for example, U.S. Pat. No. 7,217,798. 
0076. The term "heterologous' means that these domains 
are not naturally found associated with constant regions of an 
antibody. In particular, Such heterologous binding domains 
do not have the typical structure of an antibody variable 
domain consisting of 4 framework regions, FR1, FR2, FR3 
and FR4 and the 3 complementarity determining regions 
(CDRs) in-between. Each arm of the fusobody therefore com 
prises a first single chain polypeptides comprising a first 
binding domain covalently linked at the N-terminal part of a 
constant C1 heavy chain region of an antibody, and a second 
single chain polypeptide comprising a second binding 
domain covalently linked at the N-terminal part of a constant 
C light chain of an antibody. The covalent linkage may be 
direct, for example via peptidic bound or indirect, via a linker, 
for example a peptidic linker. The two heterodimers of the 
fusobody are covalently linked, for example, by at least one 
disulfide bridge at their hinge region, like an antibody struc 
ture. Examples of molecules with a fusobody structure have 
been described in the art, in particular, fuSobodies comprising 
ligand binding region of heterodimeric receptor (see for 
example international patent publications WOO1/46261 and 
WO11/076,781). 
0077. The term “polyethylene glycol” or “PEG” refers to 
a polyalkylene glycol compound or a derivative thereof, with 
or without coupling agents or derivatization with coupling or 
activating moieties. 
0078. The term “FGF21-associated disorders, and terms 
similarly used herein, includes obesity, type 1 and type 2 
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic 
fatty liver disease (NAFLD), nonalcoholic steatohepatitis 
(NASH), insulin resistance, hyperinsulinemia, glucose intol 
erance, hyperglycemia, metabolic syndrome, acute myocar 
dial infarction, hypertension, cardiovascular disease, athero 
Sclerosis, peripheral arterial disease, stroke, heart failure, 
coronary heart disease, kidney disease, diabetic complica 
tions, neuropathy, gastroparesis, disorders associated with 
severe inactivating mutations in the insulin receptor, and 
other metabolic disorders. 
0079. The term “disorders associated with severe inacti 
Vating mutations in the insulin receptor, and terms similarly 
used herein, describe conditions in subjects afflicted with 
mutations in the insulin receptor (or possible proteins directly 
downstream from it) which cause severe insulin resistance but 
are often (though not always) seen without the obesity com 
mon in Type 2 diabetes mellitus. In many ways, Subjects 
afflicted with these conditions manifest hybrid symptoms of 
Type 1 diabetes mellitus and Type 2 diabetes mellitus. Sub 
jects thereby afflicted fall into several categories of roughly 
increasing severity, including: Type A Insulin Resistance, 
Type C Insulin Resistance (AKA HAIR-AN Syndrome), 
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Rabson-Mendenhall Syndrome and finally Donohue's Syn 
drome or Leprechaunism. These disorders are associated with 
very high endogenous insulin levels, and very often, hyperg 
lycemia. Subjects thereby afflicted also present with various 
clinical features associated with “insulin toxicity, including 
hyperandrogenism, polycystic ovarian syndrome (PCOS), 
hirsuitism, and acanthosis nigricans (excessive growth and 
pigmentation) in the folds of the skin. 
0080 “Type 2 diabetes mellitus' is a condition character 
ized by excess glucose production in spite of the availability 
of insulin, and circulating glucose levels remain excessively 
high as a result of inadequate glucose clearance. 
I0081 “Type 1 diabetes mellitus' is a condition character 
ized by high blood glucose levels caused by total lack of 
insulin. This occurs when the body's immune system attacks 
the insulin-producing beta cells in the pancreas and destroys 
them. The pancreas then produces little or no insulin. 
I0082 “Glucose intolerance' or Impaired Glucose Toler 
ance (IGT) is a pre-diabetic state of dysglycemia that is asso 
ciated with increased risk of cardiovascular pathology. The 
pre-diabetic condition prevents a Subject from moving glu 
cose into cells efficiently and utilizing it as an efficient fuel 
Source, leading to elevated glucose levels in blood and some 
degree of insulin resistance. 
I0083) “Hyperglycemia' is defined as an excess of sugar 
(glucose) in the blood. 
I0084) “Hypoglycemia', also called low blood sugar, 
occurs when your blood glucose level drops too low to pro 
vide enough energy for your body’s activities. 
I0085. “Hyperinsulinemia' is defined as a higher-than-nor 
mal level of insulin in the blood. 
0086) “Insulin resistance' is defined as a state in which a 
normal amount of insulin produces a Subnormal biologic 
response. 
I0087. “Obesity.” in terms of the human subject, can be 
defined as that body weight over 20 percent above the ideal 
body weight for a given population (R. H. Williams, Textbook 
of Endocrinology, 1974, p. 904-916). 
I0088 “Diabetic complications” are problems, caused by 
high blood glucose levels, with other body functions such as 
kidneys, nerves (neuropathies), feet (foot ulcers and poor 
circulation) and eyes (e.g. retinopathies). Diabetes also 
increases the risk for heart disease and bone and joint disor 
ders. Other long-term complications of diabetes include skin 
problems, digestive problems, sexual dysfunction and prob 
lems with teeth and gums. 
I0089) “Metabolic syndrome” can be defined as a cluster of 
at least three of the following signs: abdominal fat—in most 
men, a 40-inch waist or greater, high blood Sugar—at least 
110 milligrams per deciliter (mg/dl) after fasting; high trig 
lycerides—at least 150 mg/dL in the bloodstream; low 
HDL less than 40 mg/dl; and, blood pressure of 130/85 
mmHg or higher. 
0090 “Pancreatitis” is inflammation of the pancreas. 
0091 “Dyslipidemia' is a disorder of lipoprotein metabo 
lism, including lipoprotein overproduction or deficiency. 
Dyslipidemias may be manifested by elevation of the total 
cholesterol, low-density lipoprotein (LDL) cholesterol and 
triglyceride concentrations, and a decrease in high-density 
lipoprotein (HDL) cholesterol concentration in the blood. 
0092 “Nonalcoholic fatty liver disease (NAFLD) is a 
liver disease, not associated with alcohol consumption, char 
acterized by fatty change of hepatocytes. 
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0093. “Nonalcoholic steatohepatitis (NASH) is a liver 
disease, not associated with alcohol consumption, character 
ized by fatty change of hepatocytes, accompanied by intral 
obular inflammation and fibrosis. 
0094) “Hypertension” or high blood pressure that is a tran 
sitory or Sustained elevation of systemic arterial blood pres 
Sure to a level likely to induce cardiovascular damage or other 
adverse consequences. Hypertension has been arbitrarily 
defined as a systolic blood pressure above 140 mmHg or a 
diastolic blood pressure above 90 mmHg. 
0.095 “Cardiovascular diseases” are diseases related to the 
heart or blood vessels. 
0096 Acute myocardial infarction’ occurs when there is 
interruption of the blood supply to a part of the heart. The 
resulting ischemia and oxygen shortage, ifleft untreated for a 
Sufficient period of time, can cause damage or death (infarc 
tion) of the heart muscle tissue (myocardium). 
0097. “Peripheral arterial disease” occurs when plaque 
builds up in the arteries that carry blood to the head, organs 
and limbs. Over time, plaque can harden and narrow the 
arteries which limits the flow of oxygen-rich blood to organs 
and other parts of the body. 
0.098 Atherosclerosis” is a vascular disease character 
ized by irregularly distributed lipid deposits in the intima of 
large and medium-sized arteries, causing narrowing of arte 
rial lumens and proceeding eventually to fibrosis and calcifi 
cation. Lesions are usually focal and progress slowly and 
intermittently. Limitation of blood flow accounts for most 
clinical manifestations, which vary with the distribution and 
severity of lesions. 
0099 “Stroke” is any acute clinical event, related to 
impairment of cerebral circulation, that lasts longer than 24 
hours. A stroke involves irreversible brain damage, the type 
and severity of symptoms depending on the location and 
extent of brain tissue whose circulation has been compro 
mised. 
0100 “Heart failure', also called congestive heart failure, 
is a condition in which the heart can no longer pump enough 
blood to the rest of the body. 
0101 “Coronary heart disease', also called coronary 
artery disease, is a narrowing of the Small blood vessels that 
Supply blood and oxygen to the heart. 
0102 “Kidney disease' or nephropathy is any disease of 
the kidney. Diabetic nephropathy is a major cause of morbid 
ity and mortality in people with type 1 or type 2 diabetes 
mellitus. 
0103 “Neuroapathies” are any diseases involving the cra 
nial nerves or the peripheral or autonomic nervous system. 
0104. “Gastroparesis” is weakness of gastric peristalsis, 
which results in delayed emptying of the bowels. 
0105. The critically ill patients encompassed by the 
present invention generally experience an unstable hyper 
metabolic state. This unstable metabolic state is due to 
changes in Substrate metabolism, which may lead to relative 
deficiencies in some nutrients. Generally there is an increased 
oxidation of both fat and muscle. 
0106 Moreover, critically ill patients are preferably 
patients that experience systemic inflammatory response Syn 
drome or respiratory distress. A reduction in morbidity means 
reducing the likelihood that a critically ill patient will develop 
additional illnesses, conditions, or symptoms or reducing the 
severity of additional illnesses, conditions, or symptoms. For 
example reducing morbidity may correspond to a decrease in 
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the incidence of bacteremia or sepsis or complications asso 
ciated with multiple organ failure. 
& G &g 0107 As used herein, the singular forms “a” “an and 
“the include plural references unless the content clearly 
dictates otherwise. Thus, for example, reference to “an anti 
body' includes a mixture of two or more such antibodies. 
0108. As used herein, the term “about” refers to +/-20%, 
more preferably, +/-10%, or still more preferably, +/-5% of 
a value. 
0109. The terms “polypeptide' and “protein', are used 
interchangeably and refer to a polymeric form of amino acids 
of any length, which can include coded and non-coded amino 
acids, naturally and non-naturally occurring amino acids, 
chemically or biochemically modified or derivatized amino 
acids, and polypeptides having modified peptide backbones. 
The term includes fusion proteins, including, but not limited 
to, fusion proteins with a heterologous amino acid sequence, 
fusions with heterologous and homologous leader sequences, 
with or without N-terminal methionine residues; immuno 
logically tagged proteins; and the like. 
0110. The terms “individual”, “subject”, “host” and 
“patient” are used interchangeably and refer to any subject for 
whom diagnosis, treatment, ortherapy is desired, particularly 
humans. Other subjects may include cattle, dogs, cats, guinea 
pigs, rabbits, rats, mice, horses, and the like. In some pre 
ferred embodiments the subject is a human. 
0111. As used herein, the term “sample” refers to biologi 
cal material from a patient. The sample assayed by the present 
invention is not limited to any particular type. Samples 
include, as non-limiting examples, single cells, multiple cells, 
tissues, tumors, biological fluids, biological molecules, or 
Supernatants or extracts of any of the foregoing. Examples 
include tissue removed for biopsy, tissue removed during 
resection, blood, urine, lymph tissue, lymph fluid, cerebrospi 
nal fluid, mucous, and stool samples. The sample used will 
vary based on the assay format, the detection method and the 
nature of the tumors, tissues, cells or extracts to be assayed. 
Methods for preparing samples are well known in the art and 
can be readily adapted in order to obtain a sample that is 
compatible with the method utilized. 
0112. As used herein, the term “biological molecule' 
includes, but is not limited to, polypeptides, nucleic acids, and 
saccharides. 
0113. As used herein, the term “modulating refers to a 
change in the quality or quantity of a gene, protein, or any 
molecule that is inside, outside, or on the surface of a cell. The 
change can be an increase or decrease in expression or level of 
the molecule. The term "modulates' also includes changing 
the quality or quantity of a biological function/activity includ 
ing, without limitation, the ability to lower blood glucose, 
insulin, triglyceride, or cholesterol levels; to reduce liver lipid 
or liver triglyceride levels; to reduce body weight; and to 
improve glucose tolerance, energy expenditure, or insulin 
sensitivity. 
0114. As used herein, the term “modulator” refers to a 
composition that modulates one or more physiological or 
biochemical events associated with an FGF21-associated dis 
order, such as type 1 or type 2 diabetes mellitus or a metabolic 
condition like obesity. Said events include but are not limited 
to the ability to lower blood glucose, insulin, triglyceride, or 
cholesterol levels; to reduce liver lipid or liver triglyceride 
levels; to reduce body weight; and to improve glucose toler 
ance, energy expenditure, or insulin sensitivity. 
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0115. A “gene product' is a biopolymeric product that is 
expressed or produced by a gene. A gene product may be, for 
example, an unspliced RNA, an mRNA, a splice variant 
mRNA, a polypeptide, a post-translationally modified 
polypeptide, a splice variant polypeptide etc. Also encom 
passed by this term are biopolymeric products that are made 
using an RNA gene product as a template (i.e. cDNA of the 
RNA). A gene product may be made enzymatically, recom 
binantly, chemically, or within a cell to which the gene is 
native. In some embodiments, if the gene product is proteina 
ceous, it exhibits a biological activity. In some embodiments, 
if the gene product is a nucleic acid, it can be translated into 
a proteinaceous gene product that exhibits a biological activ 
ity. 
0116 “Modulation of FGF21 activity,” as used herein, 
refers to an increase or decrease in FGF21 activity that can be 
a result of, for example, interaction of an agent with an FGF21 
polynucleotide or polypeptide, inhibition of FGF21 tran 
Scription and/or translation (e.g., through antisense or siRNA 
interaction with the FGF21 gene or FGF21 transcript, through 
modulation of transcription factors that facilitate FGF21 
expression), and the like. For example, modulation of a bio 
logical activity refers to an increase or a decrease in a bio 
logical activity. FGF21 activity can be assessed by means 
including, without limitation, assaying blood glucose, insu 
lin, triglyceride, or cholesterol levels in a subject, assessing 
FGF21 polypeptide levels, or by assessing FGF21 transcrip 
tion levels. Comparisons of FGF21 activity can also be 
accomplished by, e.g., measuring levels of an FGF21 down 
stream biomarker, and measuring increases in FGF21 signal 
ing. FGF21 activity can also be assessed by measuring: cell 
signaling; kinase activity; glucose uptake into adipocytes; 
blood insulin, triglyceride, or cholesterol level fluctuations: 
liver lipid or liver triglyceride level changes; interactions 
between FGF21 and an FGF21 receptor; or phosphorylation 
ofan FGF21 receptor. In some embodiments phosphorylation 
of an FGF21 receptor can be tyrosine phosphorylation. In 
some embodiments modulation of FGF21 activity can cause 
modulation of an FGF21-related phenotype. 
0117 Comparisons of FGF21 activity can also be accom 
plished by, e.g., measuring levels of an FGF21 downstream 
biomarker, and measuring increases in FGF21 signaling. 
FGF21 activity can also be assessed by measuring: cell sig 
naling; kinase activity; glucose uptake into adipocytes; blood 
insulin, triglyceride, or cholesterol level fluctuations; liver 
lipid or liver triglyceride level changes; interactions between 
FGF21 and a receptor (FGFR-1c, FGFR-2c, or FGFR-3c); or 
phosphorylation of an FGF21 receptor. In some embodiments 
phosphorylation of an FGF21 receptor can be tyrosine phos 
phorylation. In some embodiments modulation of FGF21 
activity can cause modulation of an FGF21-related pheno 
type. 
0118 A“FGF21 downstream biomarker” as used herein, 
is a gene or gene product, or measurable indicia of a gene or 
gene product. In some embodiments, a gene or activity that is 
a downstream marker of FGF21 exhibits an altered level of 
expression, or in a vascular tissue. In some embodiments, an 
activity of the downstream marker is altered in the presence of 
an FGF21 modulator. In some embodiments, the downstream 
markers exhibit altered levels of expression when FGF21 is 
perturbed with an FGF21 modulator of the present invention. 
FGF21 downstream markers include, without limitation, glu 
cose or 2-deoxy-glucose uptake, pERK and other phospho 
rylated or acetylated proteins or NAD levels. 
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0119. As used herein, the term "up-regulates’ refers to an 
increase, activation or stimulation of an activity or quantity. 
For example, in the context of the present invention, FGF21 
modulators may increase the activity of an FGF21 receptor. In 
one embodiment, one or more FGFR-1c, FGFR-2c, or FGFR 
3c may be upregulated in response to an FGF21 modulator. 
Upregulation can also refer to an FGF21-related activity, such 
as e.g., the ability to lower blood glucose, insulin, triglycer 
ide, or cholesterol levels; to reduce liver lipid or triglyceride 
levels; to reduce body weight; to improve glucose tolerance, 
energy expenditure, or insulin sensitivity; or to cause phos 
phorylation of an FGF21 receptor; or to increase an FGF21 
downstream marker. The FGFR21 receptor can be one or 
more of FGFR-1c, FGFR-2c, or FGFR-3c. Up-regulation 
may beat least 25%, at least 50%, at least 75%, at least 100%, 
at least 150%, at least 200%, at least 250%, at least 400%, or 
at least 500% as compared to a control. 
0.120. As used herein, the term “N-terminus’ refers to at 
least the first 20 amino acids of a protein. 
0.121. As used herein, the terms “N-terminal domain and 
“N-terminal region' are used interchangeably and refer to a 
fragment of a protein that begins at the first amino acid of the 
protein and ends at any amino acid in the N-terminal half of 
the protein. For example, the N-terminal domain of FGF21 is 
from amino acid 1 of SEQ ID NO:1 to any amino acid 
between about amino acids 10 and 105 of SEQID NO:1. 
0.122. As used herein, the term “C-terminus’ refers to at 
least the last 20 amino acids of a protein. 
(0123. As used herein, the terms “C-terminal domain” and 
“C-terminal region' are used interchangeably and refer to a 
fragment of a protein that begins at any amino acid in the 
C-terminal half of the protein and ends at the last amino acid 
of the protein. For example, the C-terminal domain of FGF21 
begins at any amino acid from amino acid 105 to about amino 
acid 200 of SEQID NO:1 and ends atamino acid 209 of SEQ 
ID NO:1. 
0.124. The term “domain” as used herein refers to a struc 
tural part of a biomolecule that contributes to a known or 
Suspected function of the biomolecule. Domains may be co 
extensive with regions orportions thereofand may also incor 
porate a portion of a biomolecule that is distinct from a 
particular region, in addition to all or part of that region. 
0.125. As used herein, the term “signal domain (also 
called 'signal sequence' or 'signal peptide') refers to a pep 
tide domain that resides in a continuous stretch of amino acid 
sequence at the N-terminal region of a precursor protein 
(often a membrane-bound or secreted protein) and is involved 
in post-translational protein transport. In many cases the sig 
nal domain is removed from the full-length protein by spe 
cialized signal peptidases after the sorting process has been 
completed. Each signal domain specifies a particular destina 
tion in the cell for the precursor protein. The signal domain of 
FGF21 is amino acids 1-28 of SEQID NO:1. 
I0126. As used herein, the term “receptor binding domain 
refers to any portion or region of a protein that contacts a 
membrane-bound receptor protein, resulting in a cellular 
response, Such as a signaling event. 
I0127. As used herein, the term “ligand binding domain 
refers to any portion or region of a fusion protein of the 
invention retaining at least one qualitative binding activity of 
a corresponding native sequence. 
I0128. The term “region” refers to a physically contiguous 
portion of the primary structure of a biomolecule. In the case 
of proteins, a region is defined by a contiguous portion of the 
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amino acid sequence of that protein. In some embodiments a 
“region' is associated with a function of the biomolecule. 
0129. The term “fragment as used herein refers to a 
physically contiguous portion of the primary structure of a 
biomolecule. In the case of proteins, a portion is defined by a 
contiguous portion of the amino acid sequence of that protein 
and refers to at least 3-5 amino acids, at least 8-10 amino 
acids, at least 11-15 amino acids, at least 17-24 amino acids, 
at least 25-30 amino acids, and at least 30-45 amino acids. In 
the case of oligonucleotides, a portion is defined by a con 
tiguous portion of the nucleic acid sequence of that oligo 
nucleotide and refers to at least 9-15 nucleotides, at least 
18-30 nucleotides, at least 33-45 nucleotides, at least 48-72 
nucleotides, at least 75-90 nucleotides, and at least 90-130 
nucleotides. In some embodiments, portions of biomolecules 
have a biological activity. In the context of the present inven 
tion, FGF21 polypeptide fragments do not comprise the entire 
FGF21 polypeptide sequence set forth in SEQID NO:1. 
0130. A “native sequence' polypeptide is one that has the 
same amino acid sequence as a polypeptide derived from 
nature. Such native sequence polypeptides can be isolated 
from nature or can be produced by recombinant or synthetic 
means. Thus, a native sequence polypeptide can have the 
amino acid sequence of naturally occurring human polypep 
tide, murine polypeptide, or polypeptide from any other 
mammalian species. 
0131. As used herein, the phrase “homologous nucleotide 
sequence.” or “homologous amino acid sequence.” or varia 
tions thereof, refers to sequences characterized by a homol 
ogy, at the nucleotide level or amino acid level, of at least a 
specified percentage and is used interchangeably with 
"sequence identity.” Homologous nucleotide sequences 
include those sequences coding for isoforms of proteins. Such 
isoforms can be expressed in different tissues of the same 
organism as a result of for example, alternative splicing of 
RNA. Alternatively, isoforms can be encoded by different 
genes. Homologous nucleotide sequences include nucleotide 
sequences encoding for a protein of a species other than 
humans, including, but not limited to, mammals. Homolo 
gous nucleotide sequences also include, but are not limited to, 
naturally occurring allelic variations and mutations of the 
nucleotide sequences set forth herein. Homologous amino 
acid sequences include those amino acid sequences which 
contain conservative amino acid Substitutions and which 
polypeptides have the same binding and/or activity. In some 
embodiments, a nucleotide or amino acid sequence is 
homologous if it has at least 60% or greater, up to 99%, 
identity with a comparator sequence. In some embodiments, 
a nucleotide or amino acid sequence is homologous if it 
shares one or more, up to 60, nucleotide?amino acid Substi 
tutions, additions, or deletions with a comparator sequence. 
In some embodiments, the homologous amino acid 
sequences have no more than 5 or no more than 3 conservative 
amino acid Substitutions. 
0132) Percent homology or identity can be determined by, 
for example, the Gap program (Wisconsin Sequence Analysis 
Package, Version 8 for UNIX, Genetics Computer Group, 
University Research Park, Madison Wis.), using default set 
tings, which uses the algorithm of Smith and Waterman (Adv. 
Appl. Math., 1981, 2, 482-489). In some embodiments, 
homology between the probe and target is between about 75% 
to about 85%. In some embodiments, nucleic acids have 
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nucleotides that are at least about 95%, about 97%, about 
98%, about 99% and about 100% homologous to SEQ ID 
NO:2, or a portion thereof. 
0.133 Homology may also be at the polypeptide level. In 
Some embodiments, constituent polypeptides of the fusion 
proteins of the invention may be at least 95% homologous to 
their full length wild-type counterparts or corresponding 
native sequences, or to portions thereof. The degree or per 
centage identity of Fusion Proteins of the invention, or por 
tions thereof, and different amino acid sequences is calcu 
lated as the number of exact matches in an alignment of the 
two sequences divided by the length of the “invention 
sequence' or the “foreign sequence', whichever is shortest. 
The result is expressed as percent identity. 
I0134. As used herein, the term “mixing refers to the 
process of combining one or more compounds, cells, mol 
ecules, and the like together in the same area. This may be 
performed, for example, in a test tube, petri dish, or any 
container that allows the one or more compounds, cells, or 
molecules, to be mixed. 
I0135. As used herein, the term “substantially purified’ 
refers to a compound (e.g., either a polynucleotide or a 
polypeptide or an antibody) that is removed from its natural 
environment and is at least 60% free, at least 75% free, and at 
least 90% free from other components with which it is natu 
rally associated. 
0.136 The term “pharmaceutically acceptable carrier' 
refers to a carrier for administration of a therapeutic agent, 
such as antibodies or a polypeptide, genes, and other thera 
peutic agents. The term refers to any pharmaceutical carrier 
that does not itself induce the production of antibodies harm 
ful to the individual receiving the composition, and which can 
be administered without undue toxicity. Suitable carriers can 
be large, slowly metabolized macromolecules such as pro 
teins, polysaccharides, polylactic acids, polyglycolic acids, 
polymeric amino acids, amino acid copolymers, lipid aggre 
gates and inactive virus particles. Such carriers are well 
known to those of ordinary skill in the art. Pharmaceutically 
acceptable carriers in therapeutic compositions can include 
liquids Such as water, saline, glycerol and ethanol. Auxiliary 
Substances, such as wetting or emulsifying agents, pH buff 
ering Substances, and the like, can also be present in Such 
vehicles. 
Enhancing the Physical Stability of the Fusion Proteins of the 
Invention 
0.137 Naturally occurring disulfide bonds, as provided by 
cysteine residues, generally increase thermodynamic stabil 
ity of proteins. Successful examples of increased thermody 
namic stability, as measured in increase of the melting tem 
perature, are multiple disulfide-bonded mutants of the 
enzymes T4 lysozyme (Matsumuraet al., PNAS 86:6562 
6566 (1989)) and barnase (Johnson et al., J. Mol. Biol. 268: 
198-208 (1997)). An aspect of the present invention is an 
enhancement of the physical stability of FGF21 in the pres 
ence of a preservative, achieved by the presence of disulfide 
bonds within the variants, which constrain the flexibility of 
wild-type FGF21 and thereby limit access of the preservative 
to the hydrophobic core of the protein. 
0.138. The second aspect of the present invention therefore 
provides variants of human FGF21, or a biologically active 
peptide thereof, with enhanced pharmaceutical stability 
engendered by the incorporation of additional disulfide 
bonds, e.g., via incorporating or substituting cysteine resi 
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Alal62Cys, Thr57Cys-Ala162Cys, Glu58Cys-Ala162Cys, 0145 As described further herein, the fusion proteins of 
Arg47Cys-Arg163Cys, Tyr18Cys-Arg163Cys, Leu49Cys 
Arg163Cys, TyrSOCys-Arg163Cys, Thr51Cys-Arg163Cys, 
Asp52Cys-Arg163Cys, Asp53Cys-Arg163Cys, Alaš4Cys 
Arg163Cys, Gln55Cys-Arg163Cys, Gln56Cys-Arg163Cys, 
Thr57Cys-Arg163Cys, Glu58Cys-Arg163Cys 
0141 Another aspect of the present invention provides 
fusion proteins comprising variants of wild-type human 
FGF21, or a biologically active peptide thereof, comprising a 
Substitution of any charged and/or polar but uncharged amino 
acid at any of the amino acid positions indicated in the first 
embodiment of the present invention combined with the sub 
stitution of a cysteine at two or more amino acid positions 
indicated in the second embodiment of the invention. 
Improvements of the Fusion Proteins of the Invention Over 
Wild Type Protein Comparators and Variants. Thereof 
0142. It is well known in the art that a significant challenge 
in the development of protein pharmaceuticals is to deal with 
the physical and chemical instabilities of proteins. This is 
even more apparent when a protein pharmaceutical formula 
tion is intended to be a multiple use, injectable formulation 
requiring a stable, concentrated and preserved solution, while 
maintaining a favorable bioactivity profile. Biophysical char 
acterization of wild-type FGF21 in the literature established 
that a concentrated protein solution (>5 mg/ml), when 
exposed to stress conditions, such as high temperature or low 
pH, lead to accelerated association and aggregation (i.e., poor 
physical stability and biopharmaceutical properties). Expo 
sure of a concentrated protein solution of FGF21 to pharma 
ceutical preservatives (e.g., m-cresol) also had a negative 
impact on physical stability. 
0143. Therefore, an embodiment of the present invention 
is to enhance physical stability of concentrated Solutions, 
while maintaining chemical stability and biological potency, 
under both physiological and preserved formulation condi 
tions. It is thought that association and aggregation may result 
from hydrophobic interactions, since, at a given protein con 
centration, temperature, and ionic strength have considerable 
impact on physical stability. For the most part, non-con 
served, presumed Surface exposed amino acid residues were 
targeted. The local environment of these residues was ana 
lyzed and, those that were not deemed structurally important 
were selected for mutagenesis. One method to initiate specific 
changes is to further decrease the pi of the protein by intro 
ducing glutamic acid residues (glutamic acid scan). It is 
hypothesized that the introduction of charged substitutes 
would inhibit hydrophobic-mediated aggregation via charge 
charge repulsion and potentially improve preservative com 
patibility. In addition, one skilled in the art would also recog 
nize that with sufficient degree of mutagenesis the p could be 
shifted into a basic pH range by the introduction of positive 
charge with or without concomitant decrease in negative 
charge, thus allowing for charge-charge repulsion. 
0144. An additional difficulty associated with therapeutic 
applications of wild-type FGF21 as a biotherapeutic, for 
instance, is that its half-life is very short in vivo (on the order 
of 0.5 and 2 h, respectively, in mouse and primate). There is 
hence a need to develop follow-up compounds that are more 
efficacious either through higher potency or longer half-life. 
The fusion proteins of the invention were developed as a way 
to achieve the desirable effects of FGF21 treatmentata higher 
potency and in a half-life-extended formulation. 
the invention have half-lives of greater than two weeks in the 
mouse, compared to the much shorter half-life of wild-type 
FGF21 and the 17 hour half-life of fusion protein Fc-L(15)- 
FGF21 (L98R, P171G, A180E) in PCT Publication WO10/ 
129,600. The fusion proteins of the invention also demon 
strate improved half-life and pharmacokinetic properties 
compared to PEGylated V76, as described herein and in U.S. 
patent application 61/415,476, filed on Nov. 19, 2010. 
0146). Furthermore, the Fc-FGF21 fusion proteins of the 
invention at 1 mpk are more efficacious than V76 at 5 mpk on 
reducing glucose, insulin, body weight and liver lipid. In a 
12-day treatment study in ob/ob mice, the fusion proteins 
show the following % changes from vehicle (all of the fusions 
are administered at 1.0 mg/kg, and V76 is administered at 5.0 
mg/kg): 
0147 Total glucose (AUC)% change from vehicle:V76 is 
-42%; V101 is -53%, V103 is -46%, and V188 is -42%; 
0.148. Total plasma insulin 96 change from vehicle: V76 is 
-46%; V101 is -82%, V103 is -69%, and V188 is -59%; 
0149 Total body weight % change from vehicle: V76 is 
-7%; V101 is -12%, V103 is -12%, and V188 is -1.1%; and 
(O150 Total liver lipid % change from vehicle: V76 is 
-30%; V101 is -44%, V103 is -50%, and V188 is -51%. 
0151. Similarly, in vitro assays reveal the same 5-fold or 
greater potency of the fusion proteins of the invention over 
V76: 
0152. In the pERK in human adipocytes assay (mean 
EC50+SEM), V76 is 21+2 nM (n=3); V101 is 1.0+0.1 nM 
(n=3), V103 is 1.3+0.2 nM (n=3), and V188 is 1.4+0.4 nM 
(n-3); 
0153. In the pERK in HEK293 with human Bklotho assay 
(mean EC50+SEM), V76 is 13+4 nM (n=5), V101 is 0.60+0. 
06 nM (n=5), V103 is 0.9-0.3 nM (n=5), and V188 is 0.4+0.1 
nM (n=3); and 
0154 In the glucose uptake in mouse adipocytes assay 
(mean EC50+SEM), V76 is 5+1 nM (n-3), V101 is 0.60+0.06 
nM (n=3), V103 is 0.60+0.07 nM (n=3), and V188 is 0.48+0. 
14 nM (n=3). 
0155 Although the embodiments of the present invention 
concern the physical and chemical stability under both physi 
ological and preserved pharmaceutical formulation condi 
tions, maintaining the biological potency of the fusion pro 
teins of the invention as compared to, e.g., wild-type FGF21 
is an important factor of consideration as well. Therefore, the 
biological potency of the proteins of the present invention is 
defined by the ability of the proteins to affect glucose uptake 
and/or the lowering of plasma glucose levels, as shown herein 
in the examples. 
0156 The proteins, polypeptides, and/or peptides of the 
invention administered according to this invention may be 
generated and/or isolated by any means known in the art. The 
most preferred method for producing the variant is through 
recombinant DNA methodologies and is well known to those 
skilled in the art. Such methods are described in Current 
Protocols in Molecular Biology (John Wiley & Sons, Inc.), 
which is incorporated herein by reference. 
0157 Additionally, the preferred embodiments include a 
biologically active peptide derived from the variant described 
herein. Such a peptide will contain at least one of the substi 
tutions described and the variant will possess biological activ 
ity. The peptide may be produced by any and all means known 
to those skilled in the art, examples of which included but are 
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not limited to enzymatic digestion, chemical synthesis or 
recombinant DNA methodologies. 
0158. It is established in the art that fragments of peptides 
of certain fibroblast growth factors are biologically active. 
See for example, Baird et al., Proc. Natl. Acad. Sci. (USA) 
85:2324-2328 (1988), and J. Cell. Phys. Suppl. 5:101-106 
(1987). Therefore, the selection of fragments or peptides of 
the variant is based on criteria known in the art. For example, 
it is known that dipeptidyl peptidase IV (DPP-IV, or DPP-4) 
is a serine type protease involved in inactivation of neuropep 
tides, endocrine peptides, and cytokines (Damme etal. Chem. 
Immunol. 72: 42-56, (1999)). The N-terminus of FGF21 
(HisProllePro) contains two dipeptides that could potentially 
be substrates to DPP-IV, resulting in a fragment of FGF21 
truncated at the N-terminus by 4 amino acids. Unexpectedly, 
this fragment of wild-type FGF21 has been demonstrated to 
retain biological activity, thus, proteins of the present inven 
tion truncated at the N-terminus by up to 4 amino acids, is an 
embodiment of the present invention. 
0159. The invention also encompasses polynucleotides 
encoding the above-described variants that may be in the 
form of RNA or in the form of DNA, which DNA includes 
cDNA, genomic DNA, and synthetic DNA. The DNA may be 
double-stranded or single-stranded. The coding sequences 
that encode the proteins of the present invention may vary as 
a result of the redundancy or degeneracy of the genetic code. 
0160 The polynucleotides that encode for the fusion pro 
teins of the invention may include the following: only the 
coding sequence for the variant, the coding sequence for the 
variant and additional coding sequence Such as a functional 
polypeptide, or a leader or secretory sequence or a pro-protein 
sequence; the coding sequence for the variant and non-coding 
sequence. Such as introns or non-coding sequence 5' and/or 3' 
of the coding sequence for the variant. Thus the term “poly 
nucleotide encoding a variant' encompasses a polynucleotide 
that may include not only coding sequence for the variant but 
also a polynucleotide, which includes additional coding and/ 
or non-coding sequence. 
0161 The invention further relates to variants of the 
described polynucleotides that encode for fragments, analogs 
and derivatives of the polypeptide that contain the indicated 
substitutions. The variant of the polynucleotide may be a 
naturally occurring allelic variant of the human FGF21 
sequence, a non-naturally occurring variant, or a truncated 
variant as described above. Thus, the present invention also 
includes polynucleotides encoding the variants described 
above, as well as variants of Such polynucleotides, which 
variants encode for a fragment, derivative or analog of the 
disclosed variant. Such nucleotide variants include deletion 
variants, Substitution variants, truncated variants, and addi 
tion or insertion variants as long as at least one of the indicated 
amino acid Substitutions of the first or second embodiments is 
present. 
0162 The polynucleotides of the invention will be 
expressed in hosts after the sequences have been operably 
linked to (i.e., positioned to ensure the functioning of) an 
expression control sequence. These expression vectors are 
typically replicable in the host organisms either as episomes 
or as an integral part of the host chromosomal DNA. Com 
monly, expression vectors will contain selection markers, 
e.g., tetracycline, neomycin, and dihydrofolate reductase, to 
permit detection of those cells transformed with the desired 
DNA sequences. The FGF21 variant can be expressed in 
mammalian cells, insect, yeast, bacterial or other cells under 
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the control of appropriate promoters. Cell free translation 
systems can also be employed to produce Such proteins using 
RNAs derived from DNA constructs of the present invention. 
0163 E. coli is a prokaryotic host useful particularly for 
cloning the polynucleotides of the present invention. Other 
microbial hosts suitable for use include Bacillus subtilus, 
Salmonella typhimurium, and various species of Serratia, 
Pseudomonas, Streptococcus, and Staphylococcus, although 
others may also be employed as a matter of choice. In these 
prokaryotic hosts, one can also make expression vectors, 
which will typically contain expression control sequences 
compatible with the host cell (e.g., an origin of replication). In 
addition, any of a number of well-known promoters may be 
present, such as the lactose promoter system, a tryptophan 
(Trp) promoter system, a beta-lactamase promoter system, or 
a promoter system from phages lambda or T7. The promoters 
will typically control expression, optionally with an operator 
sequence, and have ribosome binding site sequences and the 
like, for initiating and completing transcription and transla 
tion. 
0164. One skilled in the art of expression of proteins will 
recognize that methionine or methionine-arginine sequence 
can be introduced at the N-terminus of the mature sequence 
(SEQ ID NO: 3) for expression in E. coli and are contem 
plated within the context of this invention. Thus, unless oth 
erwise noted, proteins of the present invention expressed in E. 
coli have a methionine sequence introduced at the N-termi 
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0.165. Other microbes, such as yeast or fungi, may also be 
used for expression. Pichia pastoris, Saccharomyces cerevi 
siae, Schizosaccharomyces pombe, and Pichia angusta are 
examples of preferred yeast hosts, with suitable vectors hav 
ing expression control sequences. Such as promoters, includ 
ing 3-phosphoglycerate kinase or other glycolytic enzymes, 
and an origin of replication, termination sequences and the 
like as desired. Aspergillus niger; Trichoderma reesei; and 
Schizophyllum commune, are examples of fungi hosts, 
although others may also be employed as a matter of choice. 
0166 Mammalian tissue cell culture may also be used to 
express and produce the polypeptides of the present inven 
tion. Eukaryotic cells are actually preferred, because a num 
ber of suitable host cell lines capable of secreting intact vari 
ants have been developed in the art, and include the CHO cell 
lines, various COS cell lines, NSO cells, Syrian Hamster 
Ovary cell lines, HeLa cells, or human embryonic kidney cell 
lines (i.e. HEK293, HEK293EBNA). 
0.167 Expression vectors for these cells can include 
expression control sequences, such as an origin of replication, 
a promoter, an enhancer, and necessary processing informa 
tion sites, such as ribosome binding sites, RNA splice sites, 
polyadenylation sites, and transcriptional terminator 
sequences. Preferred expression control sequences are pro 
moters derived from SV40, adenovirus, bovine papilloma 
virus, cytomegalovirus, Raus sarcoma virus, and the like. 
Preferred polyadenylation sites include sequences derived 
from SV40 and bovine growth hormone. 
0.168. The vectors containing the polynucleotide 
sequences of interest (e.g., the fusion proteins of the invention 
and expression control sequences) can be transferred into the 
host cell by well-known methods, which vary depending on 
the type of cellular host. For example, calcium chloride trans 
fection is commonly utilized for prokaryotic cells, whereas 
calcium phosphate treatment or electroporation may be used 
for other cellular hosts. 
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0169. Various methods of protein purification may be 
employed and Such methods are known in the art and 
described, for example, in Deutscher, Methods in Enzymol 
ogy 182: 83-9 (1990) and Scopes, Protein Purification: Prin 
ciples and Practice, Springer-Verlag, NY (1982). The purifi 
cation step(s) selected will depend, for example, on the nature 
of the production process used for the fusion proteins of the 
invention. 
0170 The proteins, polypeptides, and/or peptides of the 
invention, e.g., the dual activity fusion proteins of the inven 
tion, should be formulated and dosed in a fashion consistent 
with good medical practice, taking into account the clinical 
condition of the patient, the site of delivery of the protein 
compositions, the method of administration, the scheduling 
of administration, and other factors known to practitioners. 
The “therapeutically effective amount of the fusion proteins 
of the invention for purposes herein is thus determined by 
Such considerations. 
0171 The pharmaceutical compositions of the proteins of 
the present invention may be administered by any means that 
achieve the generally intended purpose: to treat type 1 and 
type 2 diabetes mellitus, obesity, metabolic syndrome, or 
critically ill patients. Non-limiting permissible means of 
administration include, for example, by inhalation or Sup 
pository or to mucosal tissue such as by lavage to vaginal, 
rectal, urethral, buccal and Sublingual tissue, orally, nasally, 
topically, intranasally, intraperitoneally, parenterally, intrave 
nously, intramuscularly, intrasternally, by intraarticular injec 
tion, intralymphatically, interstitially, intra-arterially, subcu 
taneously, intrasynovial, transepithelial, and transdermally. 
In some embodiments, the pharmaceutical compositions are 
administered by lavage, orally or inter-arterially. Other suit 
able methods of introduction can also include rechargeable or 
biodegradable devices and slow or Sustained release poly 
meric devices. The pharmaceutical compositions of this 
invention can also be administered as part of a combinatorial 
therapy with other known metabolic agents. 
0172. The dosage administered will be dependent upon 
the age, health, and weight of the recipient, kind of concurrent 
treatment, ifany, frequency of treatment, and the nature of the 
effect desired. Compositions within the scope of the invention 
include all compositions whereinan FGF21 variant is present 
in an amount that is effective to achieve the desired medical 
effect for treatment type 1 or type 2 diabetes mellitus, obesity, 
or metabolic syndrome. While individual needs may vary 
from one patient to another, the determination of the optimal 
ranges of effective amounts of all of the components is within 
the ability of the clinician of ordinary skill. 
0173 The proteins of the present invention can be formu 
lated according to known methods to prepare pharmaceuti 
cally useful compositions. A desired formulation would be 
one that is a stable lyophilized product that is reconstituted 
with an appropriate diluent or an aqueous solution of high 
purity with optional pharmaceutically acceptable carriers, 
preservatives, excipients or stabilizers Remington’s Phar 
maceutical Sciences 16th edition (1980). The proteins of the 
present invention may be combined with a pharmaceutically 
acceptable buffer, and the pH adjusted to provide acceptable 
stability, and a pH acceptable for administration. 
0.174 For parenteral administration, in one embodiment, 
the fusion proteins of the invention are formulated generally 
by mixing one or more of them at the desired degree of purity, 
in a unit dosage injectable form (solution, Suspension, or 
emulsion), with a pharmaceutically acceptable carrier, i.e., 
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one that is non-toxic to recipients at the dosages and concen 
trations employed and is compatible with other ingredients of 
the formulation. Preferably, one or more pharmaceutically 
acceptable anti-microbial agents may be added. Phenol, 
m-cresol, and benzyl alcohol are preferred pharmaceutically 
acceptable anti-microbial agents. 
0.175 Optionally, one or more pharmaceutically accept 
able salts may be added to adjust the ionic strength or tonicity. 
One or more excipients may be added to further adjust the 
isotonicity of the formulation. Glycerin, sodium chloride, and 
mannitol are examples of an isotonicity adjusting excipient. 
0176 Those skilled in the art can readily optimize phar 
maceutically effective dosages and administration regimens 
for therapeutic compositions comprising Proteins of the 
invention, as determined by good medical practice and the 
clinical condition of the individual patient. A typical dose 
range for the proteins of the present invention will range from 
about 0.01 mg per day to about 1000 mg per day (or about 
0.05 mg per week to about 5000 mg per week administered 
once per week) for an adult. Preferably, the dosage ranges 
from about 0.1 mg per day to about 100 mg per day (or about 
0.5 mg per week to about 500 mg per week administered once 
per week), more preferably from about 1.0 mg/day to about 
10 mg/day (or about 5 mg per week to about 50 mg per week 
administered once per week). Most preferably, the dosage is 
about 1-5 ring/day (or about 5 mg per week to about 25 mg per 
week administered once per week). The appropriate dose of 
an FGF21 variant administered will result in lowering blood 
glucose levels and increasing energy expenditure by faster 
and more efficient glucose utilization, and thus is useful for 
treating type 1 and type 2 diabetes mellitus, obesity and 
metabolic syndrome. 
0177. In addition, because hyperglycemia and insulin 
resistance are common in critically ill patients given nutri 
tional Support, Some ICUs administer insulin to treat exces 
sive hyperglycemia in fed critically ill patients. In fact, recent 
studies document the use of exogenous insulin to maintain 
blood glucose at a level no higher than 110 mg per deciliter 
reduced morbidity and mortality among critically ill patients 
in the Surgical intensive care unit, regardless of whether they 
had a history of diabetes (Van den Bergheet al. N Engl J. 
Med., 345(19): 1359, (2001)). Thus, proteins of the present 
invention are uniquely suited to help restore metabolic stabil 
ity in metabolically unstable critically ill patients. Proteins of 
the invention such as those containing variants of FGF21 are 
unique in that they stimulate glucose uptake and enhances 
insulin sensitivity but do not induce hypoglycemia. 
0178. In another aspect of the present invention, proteins 
of the invention for use as a medicament for the treatment of 
obesity, type 1 and type 2 diabetes mellitus, pancreatitis, 
dyslipidemia, nonalcoholic fatty liver disease (NAFLD), 
nonalcoholic steatohepatitis (NASH), insulin resistance, 
hyperinsulinemia, glucose intolerance, hyperglycemia, meta 
bolic syndrome, acute myocardial infarction, conditions 
associated with severe inactivating mutations in the insulin 
receptor, and other metabolic disorders is contemplated. 
Site-Specific FGF21 Mutants 
0179. In some embodiments, the fusion proteins of the 
invention include additional FGF21 mutants or FGF21 ana 
logues with unnatural amino acids. 
0180. In some embodiments, the fusion proteins of the 
invention comprise FGF21 agonists with one or more of the 
following additional modifications of wild-type FGF21: 
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0181 (i) additional disulfides, unnatural amino acids, or 
modifications to promote dimerization such as formation of a 
disulfide at R154C or introduction of a cysteine at another 
site, or dimerization through a fused Fc domain, or dimer 
formation through a cross-linker such as a bifunctional PEG: 
0182 (ii) fragments of FGF21; 
0183 (ii) proteins selected to have FGF21 activity (bind 
ing to beta-klotho and binding and activation of the FGFRs); 
and 
0184 (iv) an FGF21 mimetic antibody (of various formats 
such as Fab, unibody, SvFc etc.). 
0185. In some embodiments, the fusion proteins of the 
invention comprise one or more of the following linkers: a 
simple amide bond, short peptides (particularly Ser/Gly 
repeats), additional residues from the FGF21 translated 
sequence, or a larger linker up to an entire protein (such as an 
Fc domain, an HSA-binding helix bundle, HSA, etc.). 
0186 The two moieties can also be linked by other chemi 
cal means, such as through unnatural amino acids or standard 
chemical linkers (maleimide-Cys, NHS-Lys, click, etc.) 
0187. Other embodiments of the invention include but are 
not limited to the following attachments, for half-life exten 
sion: HSA-binding lipid or small molecule or micelle to 
either the monomeric or a dimeric version of the fusion. 
0188 In certain embodiments of the invention, other 
attachments may be made to proteins, polypeptides, and/or 
peptides of the invention, to achieve half-life extension and 
other improved biological properties. They can include 
attaching PEG-cholesterol conjugates (including micelles 
and liposomes) to the proteins, polypeptides, and/or peptides 
of the invention, and/or attaching Sugars (glycosylate) to the 
proteins, polypeptides, and/or peptides of the invention. In 
still other embodiments, similar techniques are employed to 
add conjugates of, e.g., polysialic acid (PSA), hydroxyethyl 
starch (HES), albumin-binding ligands, or carbohydrate 
shields to proteins, polypeptides, and/or peptides. 
0189 The HESylation technique, for example, couples 
branched hydroxyethylstarch (HES) chains (60 kDa or 100 
kDa, highly branched amylopectin fragments from corn 
starch) to a protein, polypeptides, and/or peptides via reduc 
tive alkylation. Polsialation conjugates proteins, polypep 
tides, and/or peptides of interest with polysialic acid (PSA) 
polymers in a manner similar to PEGylation. PSA polymers 
are negatively charged, non-immunogenic polymers that 
occur naturally in the body and are available in molecular 
weights of 10-50 kD. 
0190. In still other embodiments of the invention, other 
attachments or modifications may be made to proteins, 
polypeptides, and/or peptides of the invention, to achieve 
half-life extension and other improved biological properties. 
These include the creation of recombinant PEG (rPEG) 
groups, and their attachment to the proteins, polypeptides, 
and/or peptides of the invention. As developed by the com 
pany Amunix, Inc. The rPEG technology is based on protein 
sequences with PEG-like properties that are genetically fused 
to biopharmaceuticals, avoiding the extra chemical conjuga 
tion step. rPEGs are extended half-life exenatide constructs 
that contain a long unstructured tail of hydrophilic amino 
acids, and which are capable of both increasing a protein or 
peptide's serum half-life and slowing its rate of absorption, 
thus reducing the peak-trough ratio significantly. rPEGs have 
an increased hydrodynamic radius and show an apparent 
molecular weight that is about 15-fold their actual molecular 
weight, mimicking the way PEGylation achieves a long 
serum half-life. 
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Truncated FGF21 Polypeptides 
0191) One embodiment of the present invention is directed 
to truncated forms of the mature FGF21 polypeptide (SEQID 
NO:3). This embodiment of the present invention arose from 
an effort to identify truncated FGF21 polypeptides that are 
capable of providing an activity that is similar, and in some 
instances superior, to untruncated forms of the mature FGF21 
polypeptide. 
(0192. As used herein, the term “truncated FGF21 
polypeptide' refers to an FGF21 polypeptide in which amino 
acid residues have been removed from the amino-terminal (or 
N-terminal) end of the FGF21 polypeptide, amino acid resi 
dues have been removed from the carboxyl-terminal (or 
C-terminal) end of the FGF21 polypeptide, or amino acid 
residues have been removed from both the amino-terminal 
and carboxyl-terminal ends of the FGF21 polypeptide. The 
various truncations disclosed herein were prepared as 
described herein. 
(0193 The activity of N-terminally truncated FGF21 
polypeptides and C-terminally truncated FGF21 polypep 
tides can be assayed using an in vitro phospho-ERK assay. 
Specific details of the in vitro assays that can be used to 
examine the activity of truncated FGF21 polypeptides can be 
found in the examples. 
(0194 The activity of the truncated FGF21 polypeptides of 
the present invention can also be assessed in an in vivo assay, 
such as ob/ob mice. Generally, to assess the in vivo activity of 
a truncated FGF21 polypeptide, the truncated FGF21 
polypeptide can be administered to a test animal intraperito 
neally. After a desired incubation period (e.g., one hour or 
more), a blood sample can be drawn, and blood glucose levels 
can be measured. 
(0195 a.N-Terminal Truncations 
0196. In some embodiments of the present invention, 
N-terminal truncations comprise 1, 2, 3, 4, 5, 6, 7, or 8 amino 
acid residues from the N-terminal end of the mature FGF21 
polypeptide. Truncated FGF21 polypeptides having N-termi 
nal truncations offewer than 9 amino acid residues retain the 
ability of the mature FGF21 polypeptide to lower blood glu 
cose in an individual. Accordingly, in particular embodi 
ments, the present invention encompasses truncated forms of 
the mature FGF21 polypeptide or FGF21 protein variants 
having N-terminal truncations of 1,2,3,4, 5, 6, 7, or 8 amino 
acid residues. 
0.197 b. C-Terminal Truncations 
0.198. In some embodiments of the present invention, 
C-terminal truncations comprise 1,2,3,4,5,6,7,8,9, 10, 11, 
or 12 amino acid residues from the C-terminal end of the 
mature FGF21 polypeptide. Truncated FGF21 polypeptides 
having C-terminal truncations of fewer than 13 amino acid 
residues exhibited an efficacy of at least 50% of the efficacy of 
wild-type FGF21 in an in vitro ELK-luciferase assay (Yie J. et 
al. FEBS Letts 583:19-24 (2009)), indicating that these 
FGF21 mutants retain the ability of the mature FGF21 
polypeptide to lower blood glucose in an individual. Accord 
ingly, in particular embodiments, the present invention 
encompasses truncated forms of the mature FGF21 polypep 
tide or FGF21 protein variants having C-terminal truncations 
of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 amino acid residues. 
(0199 c. N-Terminal and C-Terminal Truncations 
0200. In some embodiments of the present invention, trun 
cated FGF21 polypeptides can have a combination of N-ter 
minal and C-terminal truncations. Truncated FGF21 
polypeptides having a combination of N-terminal and C-ter 
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minal truncations share the activity of corresponding trun 
cated FGF21 polypeptides having either the N-terminal or 
C-terminal truncations alone. In other words, truncated 
FGF21 polypeptides having both N-terminal truncations of 
fewer than 9 amino acid residues and C-terminal truncations 
of fewer than 13 amino acid residues possess similar or 
greater blood glucose-lowering activity as truncated FGF21 
polypeptides having N-terminal truncations of fewer than 9 
amino acid residues or truncated FGF21 polypeptides having 
C-terminal truncations offewer than 13 amino acid residues. 
Accordingly, in particular embodiments, the present inven 
tion encompasses truncated forms of the mature FGF21 
polypeptide or FGF21 protein variants having both N-termi 
nal truncations of 1, 2, 3, 4, 5, 6, 7, or 8 amino acid residues 
and C-terminal truncations of 1,2,3,4,5,6,7,8,9, 10, 11, or 
12 amino acid residues. 
0201 As with all FGF21 variants of the present invention, 
truncated FGF21 polypeptides can optionally comprise an 
amino-terminal methionine residue, which can be introduced 
by directed mutation or as a result of a bacterial expression 
process. 
0202 The truncated FGF21 polypeptides of the present 
invention can be prepared as described in the examples 
described herein. Those of ordinary skill in the art, familiar 
with Standard molecular biology techniques, can employ that 
knowledge, coupled with the instant disclosure, to make and 
use the truncated FGF21 polypeptides of the present inven 
tion. Standard techniques can be used for recombinant DNA, 
oligonucleotide synthesis, tissue culture, and transformation 
(e.g., electroporation, lipofection). See, e.g., Sambrook et al., 
Molecular Cloning: A Laboratory Manual, supra, which is 
incorporated herein by reference for any purpose. Enzymatic 
reactions and purification techniques can be performed 
according to manufacturer's specifications, as commonly 
accomplished in the art, or as described herein. Unless spe 
cific definitions are provided, the nomenclatures utilized in 
connection with, and the laboratory procedures and tech 
niques of analytical chemistry, synthetic organic chemistry, 
and medicinal and pharmaceutical chemistry described 
herein are those well known and commonly used in the art. 
Standard techniques can be used for chemical syntheses; 
chemical analyses; pharmaceutical preparation, formulation, 
and delivery; and treatment of patients. 
0203 The truncated FGF21 polypeptides of the present 
invention can also be fused to another entity, which can 
impart additional properties to the truncated FGF21 polypep 
tide. In one embodiment of the present invention, a truncated 
FGF21 polypeptide can be fused to an IgG constant domain or 
fragment thereof (e.g., the Fc region), Human Serum Albu 
min (HSA), or albumin-binding polypeptides. Such fusion 
can be accomplished using known molecular biological 
methods and/or the guidance provided herein. The benefits of 
Such fusion polypeptides, as well as methods for making Such 
fusion polypeptides, are discussed in more detail herein. 
FGF21 Fusion Proteins 
0204 As used herein, the term “FGF21 fusion polypep 
tide' or “FGF21 fusion protein’ refers to a fusion of one or 
more amino acid residues (such as a heterologous protein or 
peptide) at the N-terminus or C-terminus of any FGF21 pro 
tein variant described herein. 
0205 FGF21 fusion proteins can be made by fusing het 
erologous sequences at either the N-terminus or at the C-ter 
minus of, for example, an FGF21 protein variant, as defined 
20 
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herein. As described herein, a heterologous sequence can be 
anamino acid sequence or a non-amino acid-containing poly 
mer. Heterologous sequences can be fused either directly to 
the FGF21 protein variant or via a linker or adapter molecule. 
A linker or adapter molecule can be one or more amino acid 
residues (or-mers), e.g., 1, 2, 3, 4, 5, 6, 7, 8, or 9 residues (or 
-mers), preferably from 10 to 50 amino acid residues (or 
-mers), e.g., 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 30, 
35, 40, 45, or 50 residues (or -mers), and more preferably 
from 15 to 35 amino acid residues (or -mers). A linker or 
adapter molecule can also be designed with a cleavage site for 
a DNA restriction endonuclease or for a protease to allow for 
the separation of the fused moieties. 
0206 Heterologous peptides and polypeptides include, 
but are not limited to, an epitope to allow for the detection 
and/or isolation of an FGF21 protein variant; a transmem 
brane receptor protein or a portion thereof. Such as an extra 
cellular domain or a transmembrane and intracellular 
domain; a ligand or a portion thereof which binds to a trans 
membrane receptor protein; an enzyme or portion thereof 
which is catalytically active; a polypeptide or peptide which 
promotes oligomerization, such as a leucine Zipper domain; a 
polypeptide or peptide which increases stability, Such as an 
immunoglobulin constant region; a functional or non-func 
tional antibody, or a heavy or light chain thereof, and a 
polypeptide which has an activity, Such as a therapeutic activ 
ity, different from the FGF21 protein variants of the present 
invention. Also encompassed by the present invention are 
FGF21 mutants fused to human serum albumin (HSA). 
0207 a. Fc Fusions 
0208. In one embodiment of the present invention, an 
FGF21 protein variant is fused to one or more domains of an 
Fc region of human IgG. Antibodies comprise two function 
ally independent parts, a variable domain known as “Fab.” 
that binds an antigen, and a constant domain known as "Fc. 
that is involved in effector functions such as complement 
activation and attack by phagocytic cells. An Fc has a long 
serum half-life, whereas a Fab is short-lived (Capon et al., 
1989, Nature 337: 525-31). When joined together with a 
therapeutic protein, an Fc domain can provide longer half-life 
or incorporate Such functions as Fc receptor binding, protein 
A binding, complement fixation, and perhaps even placental 
transfer (Capon et al., 1989). 
(0209 Throughout the disclosure, Fc-FGF21 refers to a 
fusion protein in which the Fc sequence is fused to the N-ter 
minus of FGF21. Similarly, throughout the disclosure, 
FGF21-Fc refers to a fusion protein in which the Fc sequence 
is fused to the C-terminus of FGF21. 
0210 Preferred embodiments of the invention are 
Fc-FGF21 fusion proteins comprising FGF21 variants as 
defined herein. Particularly preferred embodiments are Fc 
FGF21 fusion proteins comprising a modified Fc fragment 
(e.g., an FcLALA) and FGF21 variants as defined herein. 
0211 Fusion protein can be purified, for example, by the 
use of a Protein A affinity column. Peptides and proteins fused 
to an Fc region have been found to exhibit a substantially 
greater half-life in vivo than the unfused counterpart. Also, a 
fusion to an Fc region allows for dimerization/multimeriza 
tion of the fusion polypeptide. The Fc region can be a natu 
rally occurring Fc region, or can be altered to improve certain 
qualities, such as therapeutic qualities, circulation time, or 
reduced aggregation. 
0212. Useful modifications of protein therapeutic agents 
by fusion with the “Fc domain of an antibody are discussed 
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in detail in PCT Publication No. WOOO/O24782. This docu 
ment discusses linkage to a "vehicle'. Such as polyethylene 
glycol (PEG), dextran, or an Fc region. 
0213 b. Fusion Protein Linkers 
0214. When forming the fusion proteins of the present 
invention, a linker can, but need not, be employed. When 
present, the linker's chemical structure may not critical, since 
it serves primarily as a spacer. The linker can be made up of 
amino acids linked together by peptide bonds. In some 
embodiments of the present invention, the linker is made up 
of from 1 to 20 amino acids linked by peptide bonds, wherein 
the amino acids are selected from the 20 naturally occurring 
amino acids. In various embodiments, the 1 to 20 amino acids 
are selected from the amino acids glycine, serine, alanine, 
proline, asparagine, glutamine, and lysine. In some embodi 
ments, a linker is made up of a majority of amino acids that are 
sterically unhindered, such as glycine and alanine. In some 
embodiments, linkers are polyglycines, polyalanines, combi 
nations of glycine and alanine (such as poly(Gly-Ala)), or 
combinations of glycine and serine (such as poly(Gly-Ser)). 
While a linker of 15 amino acid residues has been found to 
work particularly well for FGF21 fusion proteins, the present 
invention contemplates linkers of any length or composition. 
0215. The linkers described herein are exemplary, and 
linkers that are much longer and which include other residues 
are contemplated by the present invention. Non-peptide link 
ers are also contemplated by the present invention. For 
example, alkyl linkers such as can be used. These alkyl linkers 
can further be substituted by any non-sterically hindering 
group, including, but not limited to, a lower alkyl (e.g., 
C1-C6), lower acyl, halogen (e.g., Cl, Br), CN. NH2, or 
phenyl. An exemplary non-peptide linker is a polyethylene 
glycol linker, wherein the linker has a molecular weight of 
100 to 5000 kD, for example, 100 to 500 kD. 
Chemically-Modified Fusion Proteins 
0216 Chemically modified forms of the fusion proteins 
described herein, including, e.g., truncated and variant forms 
of the FGF21 fusions described herein, can be prepared by 
one skilled in the art, given the disclosures described herein. 
Such chemically modified Fusion Proteins are altered such 
that the chemically modified mutant is different from the 
unmodified mutant, either in the type or location of the mol 
ecules naturally attached to the mutant. Chemically modified 
mutants can include molecules formed by the deletion of one 
or more naturally-attached chemical groups. 
0217. In one embodiment, proteins of the present inven 
tion can be modified by the covalent attachment of one or 
more polymers. For example, the polymer selected is typi 
cally water-soluble so that the protein to which it is attached 
does not precipitate in an aqueous environment, such as a 
physiological environment. Included within the scope of suit 
able polymers is a mixture of polymers. Preferably, for thera 
peutic use of the end-product preparation, the polymer will be 
pharmaceutically acceptable. Non-water soluble polymers 
conjugated to proteins of the present invention also form an 
aspect of the invention. 
0218 Exemplary polymers each can be of any molecular 
weight and can be branched or unbranched. The polymers 
each typically have an average molecular weight of between 
about 2 kDa to about 100 kDa (the term “about indicating 
that in preparations of a water-soluble polymer, Some mol 
ecules will weigh more and some less than the Stated molecu 
lar weight). The average molecular weight of each polymer is 
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preferably between about 5 kDa and about 50 kDa, more 
preferably between about 12 kDa and about 40kDa, and most 
preferably between about 20 kDa and about 35 kDa. 
0219 Suitable water-soluble polymers or mixtures thereof 
include, but are not limited to, N-linked or O-linked carbo 
hydrates, Sugars, phosphates, polyethylene glycol (PEG) (in 
cluding the forms of PEG that have been used to derivatize 
proteins, including mono-(C1-C10), alkoxy-, or aryloxy 
polyethylene glycol), monomethoxy-polyethylene glycol, 
dextran (Such as low molecular weight dextran of for 
example, about 6 kD), cellulose, or other carbohydrate based 
polymers, poly-(N-vinyl pyrrolidone) polyethylene glycol, 
propylene glycol homopolymers, polypropylene oxide/ethyl 
ene oxide co-polymers, polyoxyethylated polyols (e.g., glyc 
erol), and polyvinyl alcohol. Also encompassed by the 
present invention are bifunctional crosslinking molecules 
that can be used to prepare covalently attached FGF21 protein 
variant multimers. Also encompassed by the present inven 
tion are FGF21 mutants covalently attached to polysialic 
acid. 
0220 Polysaccharide polymers are another type of water 
soluble polymer that can be used for protein modification. 
Therefore, the fusion proteins of the invention fused to a 
polysaccharide polymer form embodiments of the present 
invention. Dextrans are polysaccharide polymers comprised 
of individual subunits of glucose predominantly linked by 
alpha 1-6 linkages. The dextran itself is available in many 
molecular weight ranges, and is readily available in molecu 
lar weights from about 1 kD to about 70 kD. Dextran is a 
suitable water-soluble polymer for use as a vehicle by itselfor 
in combination with another vehicle (e.g., Fc). See, e.g., 
International Publication No. WO96/11953. The use of dex 
tran conjugated to therapeutic or diagnostic immunoglobu 
lins has been reported. See, e.g., European Patent Publication 
No. 0315 456, which is hereby incorporated by reference. 
The present invention also encompasses the use of dextran of 
about 1 kD to about 20 kD. 
0221. In general, chemical modification can be performed 
under any suitable condition used to react a protein with an 
activated polymer molecule. Methods for preparing chemi 
cally modified polypeptides will generally comprise the steps 
of: (a) reacting the polypeptide with the activated polymer 
molecule (such as a reactive ester or aldehyde derivative of 
the polymer molecule) under conditions whereby a FGF21 
protein variant becomes attached to one or more polymer 
molecules, and (b) obtaining the reaction products. The opti 
mal reaction conditions will be determined based on known 
parameters and the desired result. For example, the larger the 
ratio of polymer molecules to protein, the greater the percent 
age of attached polymer molecule. In one embodiment of the 
present invention, chemically modified FGF21 mutants can 
have a single polymer molecule moiety at the amino-terminus 
(see, e.g., U.S. Pat. No. 5,234,784) 
0222. In another embodiment of the present invention, 
Proteins of the invention can be chemically coupled to biotin. 
The biotin/Proteins of the invention are then allowed to bind 
to avidin, resulting in tetravalent avidin/biotin/Proteins of the 
invention. Proteins of the invention can also be covalently 
coupled to dinitrophenol (DNP) or trinitrophenol (TNP) and 
the resulting conjugates precipitated with anti-DNP or anti 
TNP-IgM to form decameric conjugates with a valency of 10. 
0223 Generally, conditions that can be alleviated or 
modulated by the administration of the present chemically 
modified FGF21 mutants include those described herein for 
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Proteins of the invention. However, the chemically modified 
FGF21 mutants disclosed herein can have additional activi 
ties, enhanced or reduced biological activity, or other charac 
teristics, such as increased or decreased half-life, as com 
pared to unmodified FGF21 mutants. 
Therapeutic Compositions of Fusion Proteins and 
Administration Thereof 
0224. The present invention also provides therapeutic 
compositions comprising one or more of the fusion proteins 
of the invention described herein and in admixture with a 
pharmaceutically or physiologically acceptable formulation 
agent orpharmaceutically acceptable carrier selected for Suit 
ability with the mode of administration. The compositions are 
specifically contemplated in light of, e.g., the identification of 
fusions proteins exhibiting enhanced properties. 
0225. In some embodiments the therapeutic compositions 
are prepared as injectables, either as liquid Solutions or Sus 
pensions; Solid forms suitable for solution in, or Suspension 
in, liquid vehicles prior to injection can also be prepared. 
Liposomes are included within the definition of a pharmaceu 
tically acceptable carrier. Pharmaceutically acceptable salts 
can also be present in the pharmaceutical composition, e.g., 
mineral acid salts such as hydrochlorides, hydrobromides, 
phosphates, Sulfates, and the like; and the salts of organic 
acids such as acetates, propionates, malonates, benzoates, 
and the like. A thorough discussion of pharmaceutically 
acceptable excipients is available in Remington: The Science 
and Practice of Pharmacy (1995) Alfonso Gennaro, Lippin 
cott, Williams, & Wilkins. 
0226. Acceptable formulation materials preferably are 
nontoxic to recipients at the dosages and concentrations 
employed. 
0227. The pharmaceutical composition can contain for 
mulation materials for modifying, maintaining, or preserv 
ing, for example, the pH, osmolarity, Viscosity, clarity, color, 
isotonicity, odor, Sterility, stability, rate of dissolution or 
release, adsorption, or penetration of the composition. Suit 
able formulation materials include, but are not limited to, 
amino acids (such as glycine, glutamine, asparagine, argin 
ine, or lysine), antimicrobials, antioxidants (such as ascorbic 
acid, Sodium sulfite, or sodium hydrogen-sulfite), buffers 
(such as borate, bicarbonate, Tris-HCl, citrates, phosphates, 
or other organic acids), bulking agents (such as mannitol or 
glycine), chelating agents (such as ethylenediamine tetraace 
tic acid (EDTA)), complexing agents (such as caffeine, poly 
vinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta 
cyclodextrin), fillers, monosaccharides, disaccharides, and 
other carbohydrates (such as glucose, mannose, or dextrins), 
proteins (such as serum albumin, gelatin, or immunoglobu 
lins), coloring, flavoring and diluting agents, emulsifying 
agents, hydrophilic polymers (such as polyvinylpyrrolidone), 
low molecular weight polypeptides, salt-forming counterions 
(such as sodium), preservatives (such as benzalkonium chlo 
ride, benzoic acid, salicylic acid, thimerosal, phenethyl alco 
hol, methylparaben, propylparaben, chlorhexidine, Sorbic 
acid, or hydrogen peroxide), solvents (such as glycerin, pro 
pylene glycol, or polyethylene glycol), Sugar alcohols (such 
as mannitol or Sorbitol), Suspending agents, Surfactants or 
wetting agents (such as pluronics; PEG, Sorbitan esters; 
polysorbates such as polysorbate 20 or polysorbate 80; triton; 
tromethamine; lecithin; cholesterol or tyloxapal), stability 
enhancing agents (such as Sucrose or Sorbitol), tonicity 
enhancing agents (such as alkali metal halides; preferably 
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Sodium or potassium chloride; or mannitol Sorbitol), delivery 
vehicles, diluents, excipients and/or pharmaceutical adju 
vants (see, e.g., Remington's Pharmaceutical Sciences (18th 
Ed., A. R. Gennaro, ed., Mack Publishing Company 1990), 
and Subsequent editions of the same, incorporated herein by 
reference for any purpose). 
0228. The optimal pharmaceutical composition will be 
determined by a skilled artisan depending upon, for example, 
the intended route of administration, delivery format, and 
desired dosage (see, e.g., Remington’s Pharmaceutical Sci 
ences, Supra). Such compositions can influence the physical 
state, stability, rate of in vivo release, and rate of in vivo 
clearance of the fusion protein of the invention. 
0229. The primary vehicle or carrier in a pharmaceutical 
composition can be either aqueous or non-aqueous in nature. 
For example, a suitable vehicle or carrier for injection can be 
water, physiological saline Solution, or artificial cerebrospi 
nal fluid, possibly Supplemented with other materials com 
mon in compositions for parenteral administration. Neutral 
buffered saline or saline mixed with serum albumin are fur 
ther exemplary vehicles. Other exemplary pharmaceutical 
compositions comprise Tris buffer of about pH 7.0-8.5, or 
acetate buffer of about pH 4.0–5.5, which can further include 
sorbitol or a suitable substitute. In one embodiment of the 
present invention, dual function pharmaceutical composi 
tions can be prepared for storage by mixing the selected 
composition having the desired degree of purity with optional 
formulation agents (Remington's Pharmaceutical Sciences, 
Supra) in the form of a lyophilized cake or an aqueous solu 
tion. Further, the dual function protein product can be formu 
lated as a lyophilizate using appropriate excipients such as 
SUCOS. 
0230. The pharmaceutical compositions containing the 
fusion proteins of the invention can be selected for parenteral 
delivery. Alternatively, the compositions can be selected for 
inhalation or for delivery through the digestive tract, such as 
orally. The preparation of Such pharmaceutically acceptable 
compositions is within the skill of the art. 
0231. The formulation components are present in concen 
trations that are acceptable to the site of administration. For 
example, buffers are used to maintain the composition at 
physiological pH or at a slightly lower pH, typically within a 
pH range of from about 5 to about 8. 
0232. When parenteral administration is contemplated, 
the therapeutic compositions for use in this invention can be 
in the form of a pyrogen-free, parenterally acceptable, aque 
ous Solution comprising the desired dual function protein in a 
pharmaceutically acceptable vehicle. A particularly Suitable 
vehicle for parenteral injection is sterile distilled water in 
which a dual function protein is formulated as a sterile, iso 
tonic Solution, properly preserved. Yet another preparation 
can involve the formulation of the desired molecule with an 
agent, such as injectable microspheres, bio-erodible particles, 
polymeric compounds (such as polylactic acid or polygly 
colic acid), beads, or liposomes, that provides for the con 
trolled or sustained release of the product which can then be 
delivered via a depot injection. Hyaluronic acid can also be 
used, and this can have the effect of promoting Sustained 
duration in the circulation. Other suitable means for the intro 
duction of the desired molecule include implantable drug 
delivery devices. 
0233. In one embodiment, a pharmaceutical composition 
can beformulated for inhalation. For example, a dual function 
protein of the invention can beformulated as a dry powder for 
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inhalation. Dual function protein inhalation Solutions can 
also be formulated with a propellant for aerosol delivery. In 
yet another embodiment, solutions can be nebulized. Pulmo 
nary administration is further described in International Pub 
lication No. WO 94/20069, which describes the pulmonary 
delivery of chemically modified proteins. 
0234. It is also contemplated that certain formulations can 
be administered orally. In one embodiment of the present 
invention, Fusion Proteins of the invention that are adminis 
tered in this fashion can be formulated with or without those 
carriers customarily used in the compounding of solid dosage 
forms such as tablets and capsules. For example, a capsule 
can be designed to release the active portion of the formula 
tion at the point in the gastrointestinal tract when bioavail 
ability is maximized and pre-systemic degradation is mini 
mized. Additional agents can be included to facilitate 
absorption of the fusion proteins of the invention. Diluents, 
flavorings, low melting point waxes, vegetable oils, lubri 
cants, Suspending agents, tablet disintegrating agents, and 
binders can also be employed. 
0235 Another pharmaceutical composition can involve an 
effective quantity of the fusion proteins of the invention in a 
mixture with non-toxic excipients that are suitable for the 
manufacture of tablets. By dissolving the tablets in sterile 
water, or another appropriate vehicle, solutions can be pre 
pared in unit-dose form. Suitable excipients include, but are 
not limited to, inert diluents, such as calcium carbonate, 
Sodium carbonate or bicarbonate, lactose, or calcium phos 
phate; or binding agents, such as starch, gelatin, or acacia; or 
lubricating agents such as magnesium Stearate, Stearic acid, 
or talc. 
0236 Additional pharmaceutical compositions compris 
ing Fusion Proteins of the invention will be evident to those 
skilled in the art, including formulations involving Fusion 
Proteins of the invention in sustained- or controlled-delivery 
formulations. Techniques for formulating a variety of other 
Sustained- or controlled-delivery means, such as liposome 
carriers, bio-erodible microparticles or porous beads and 
depot injections, are also known to those skilled in the art 
(see, e.g., International Publication No.WO 93/15722, which 
describes the controlled release of porous polymeric micro 
particles for the delivery of pharmaceutical compositions, 
and Wischke & Schwendeman, 2008, Int. J. Pharm. 364: 
298-327, and Freiberg & Zhu, 2004, Int. J. Pharm. 282: 1-18, 
which discuss microsphere/microparticle preparation and 
use). 
0237 Additional examples of sustained-release prepara 
tions include semipermeable polymer matrices in the form of 
shaped articles, e.g. films, or microcapsules. Sustained 
release matrices can include polyesters, hydrogels, polylac 
tides (U.S. Pat. No. 3,773.919 and European Patent No. 0.058 
481), copolymers of L-glutamic acid and gamma ethyl-L- 
glutamate (Sidman et al., 1983, Biopolymers 22: 547-56), 
poly(2-hydroxyethyl-methacrylate) (Langer et al., 1981, J. 
Biomed. Mater. Res. 15: 167-277 and Langer, 1982, Chem. 
Tech. 12: 98-105), ethylene vinyl acetate (Langer et al., 
supra) or poly-D-3-hydroxybutyric acid (European Patent 
No. 0 133988). Sustained-release compositions can also 
include liposomes, which can be prepared by any of several 
methods known in the art. See, e.g., Epstein et al., 1985, Proc. 
Natl. Acad. Sci. U.S.A. 82: 3688-92; and European Patent 
Nos. 0.036 676, O 088 046, and 0 143 949. 
0238. The pharmaceutical compositions of the invention 
to be used for in vivo administration typically must be sterile. 
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This can be accomplished by filtration through sterile filtra 
tion membranes. Where the composition is lyophilized, ster 
ilization using this method can be conducted either prior to, or 
following, lyophilization and reconstitution. The composi 
tion for parenteral administration can be stored in lyophilized 
form or in a solution. In addition, parenteral compositions 
generally are placed into a container having a sterile access 
port, for example, an intravenous Solution bag or vial having 
a stopper pierceable by a hypodermic injection needle. 
0239. Once the pharmaceutical composition has been for 
mulated, it can be stored in sterile vials as a solution, Suspen 
Sion, gel, emulsion, Solid, or as a dehydrated or lyophilized 
powder. Such formulations can be stored either in a ready-to 
use form or in a form (e.g., lyophilized) requiring reconstitu 
tion prior to administration. 
0240. In a specific embodiment, the present invention is 
directed to kits for producing a single-dose administration 
unit. The kits can each contain both a first container having a 
dried protein and a second container having an aqueous for 
mulation. Also included within the scope of this invention are 
kits containing single and multi-chambered pre-filled 
Syringes (e.g., liquid Syringes and lyosyringes). 
Dosages of Fusion Proteins and Administration Thereof 
0241 The effective amount of an pharmaceutical compo 
sition of the invention to be employed therapeutically will 
depend, for example, upon the therapeutic context and objec 
tives. One skilled in the art will appreciate that the appropriate 
dosage levels for treatment will thus vary depending, in part, 
upon the molecule delivered, the indication for which the 
fusion protein variant is being used, the route of administra 
tion, and the size (body weight, body Surface, or organ size) 
and condition (the age and general health) of the patient. 
Accordingly, the clinician cantiter the dosage and modify the 
route of administration to obtain the optimal therapeutic 
effect. A typical dosage can range from about 0.1 ug/kg to up 
to about 100 mg/kg or more, depending on the factors men 
tioned above. In other embodiments, the dosage can range 
from 0.1 ug/kg up to about 100 mg/kg, or 1 ug/kg up to about 
100 mg/kg. 
0242. The frequency of dosing will depend upon the phar 
macokinetic parameters of the dual function protein in the 
formulation being used. Typically, a clinician will administer 
the composition until a dosage is reached that achieves the 
desired effect. The composition can therefore be adminis 
tered as a single dose, as two or more doses (which may or 
may not contain the same amount of the desired molecule) 
over time, or as a continuous infusion via an implantation 
device or catheter. Further refinement of the appropriate dos 
age is routinely made by those of ordinary skill in the art and 
is within the ambit of tasks routinely performed by them. 
Appropriate dosages can be ascertained through use of appro 
priate dose-response data. 
0243 The route of administration of the pharmaceutical 
composition is in accord with known methods, e.g., orally; 
through injection by intravenous, intraperitoneal, intracere 
bral (intraparenchymal), intracerebroventricular, intramus 
cular, intraarterial, intraportal, or intralesional routes; by Sus 
tained release systems (which may also be injected); or by 
implantation devices. Where desired, the compositions can be 
administered by bolus injection or continuously by infusion, 
or by implantation device. 
0244 Alternatively or additionally, the composition can 
be administered locally via implantation of a membrane, 
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sponge, or other appropriate material onto which the desired 
molecule has been absorbed or encapsulated. Where an 
implantation device is used, the device can be implanted into 
any suitable tissue or organ, and delivery of the desired mol 
ecule can be via diffusion, timed-release bolus, or continuous 
administration. 
Therapeutic Uses of Fusion Proteins 
0245 Proteins of the invention can be used to treat, diag 
nose, ameliorate, or prevent a number of diseases, disorders, 
or conditions, including, but not limited to metabolic disor 
ders. In one embodiment, the metabolic disorder to be treated 
is diabetes, e.g., type 2 diabetes mellitus. In another embodi 
ment, the metabolic disorder is obesity. Other embodiments 
include metabolic conditions or disorders such as type 1 
diabetes mellitus, pancreatitis, dyslipidemia, nonalcoholic 
fatty liver disease (NAFLD), nonalcoholic steatohepatitis 
(NASH), insulin resistance, hyperinsulinemia, glucose intol 
erance, hyperglycemia, metabolic syndrome, hypertension, 
cardiovascular disease, acute myocardial infarction, athero 
Sclerosis, peripheral arterial disease, stroke, heart failure, 
coronary heart disease, kidney disease, diabetic complica 
tions, neuropathy, disorders associated with severe inactivat 
ing mutations in the insulin receptor, gastroparesis and other 
metabolic disorders. 
0246. In application, a disorder or condition Such as type 1 
or type 2 diabetes mellitus or obesity can be treated by admin 
istering an FGF21 protein variant as described herein to a 
patient in need thereof in the amount of a therapeutically 
effective dose. The administration can be performed as 
described herein, such as by IV injection, intraperitoneal 
injection, intramuscular injection, or orally in the form of a 
tablet or liquid formation. In most situations, a desired dosage 
can be determined by a clinician, as described herein, and can 
represent a therapeutically effective dose of the FGF21 
mutant polypeptide. It will be apparent to those of skill in the 
art that a therapeutically effective dose of FGF21 mutant 
polypeptide will depend, inter alia, upon the administration 
schedule, the unit dose of antigen administered, whether the 
nucleic acid molecule or polypeptide is administered in com 
bination with other therapeutic agents, the immune status and 
the health of the recipient. The term “therapeutically effective 
dose” as used herein, means that amount of FGF21 mutant 
polypeptide that elicits the biological or medicinal response 
in a tissue system, animal, or human being sought by a 
researcher, medical doctor, or other clinician, which includes 
alleviation of the symptoms of the disease or disorder being 
treated. 
0247 Having now described the present invention in 
detail, the same will be more clearly understood by reference 
to the following examples, which are included herewith for 
purposes of illustration only and are not intended to be lim 
iting of the invention. 
0248. The practice of the present invention will employ, 
unless otherwise indicated, conventional methods of chemis 
try, biochemistry, molecular biology, immunology and phar 
macology, within the skill of the art. Such techniques are 
explained fully in the literature. See, e.g., Remington's Phar 
maceutical Sciences, 18th Edition (Easton, Pa.; Mack Pub 
lishing Company, 1990); Methods In Enzymology (S. Colow 
ick and N. Kaplan, eds., Academic Press, Inc.); and 
Handbook of Experimental Immunology, Vols. I-IV (D. M. 
Weir and C. C. Blackwell, eds., 1986, Blackwell Scientific 
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Publications); and Sambrook et al., Molecular Cloning: A 
Laboratory Manual (2nd Edition, 1989). 
EXAMPLES 
Example 1 
Preparation of FGF21 Variant Proteins 
0249 Expression Construct for FGF21 V76: 
(0250. The FGF21 variants were cloned into the modified 
E. coli expression vector pET30a, described by Achmuller et 
al. (2007) (Nature Methods 4:1037-1043), to generate in 
frame fusions to a hexa-histidine tag followed by the N'- 
EDDIE tag at the N-terminus of FGF21 (aa 33-209). 
(0251 Expression and Purification of FGF21 V76: 
0252. The pET30a-His-N-EDDIE-FGF21 expression 
plasmid was transformed into E. coli BL21 Star (DE3) com 
petent cells (Invitrogen). Overnight growth from a single 
colony of freshly transformed cells was carried out in 50 mL 
of Terrific Broth (TB) containing 50 ug/mL of kanamycin at 
37°C. The pre-culture was transferred into 1 L of TB medium 
with kanamycin and cultured in baffled flasks at 37°C. with 
shaking at 250 rpm. After 6 hour of culture, expression of 
FGF21 was induced by the addition of IPTG at a final con 
centration of 1 mM, and the cultures were grown overnight at 
37°C. The cells were then harvested and resuspended into 50 
mL of ice-cold lysis buffer; 50 mM Tris-HCl, pH 8, 150 mM 
NaCl, 1 mM EDTA, followed by lysis using a Microfluid 
ZerTM. 
0253 Inclusion bodies (IBs) were precipitated by cen 
trifugation at 30,000xg for 1 hour at 4°C. The IBs were 
washed with 50 mM Tris-HCl, pH 8, 150 mM. NaCl and then 
dissolved into 30 mL of dissolving buffer; 10 mM Tris-HCl, 
pH8, 100mMNaHPO, 6 MGnHC1. The dissolved IBs were 
clarified by centrifugation at 30,000xg for 1 hour at 25°C. 
The IB solution was loaded onto a 5 mL column of Ni-NTA 
high performance resin (GE Healthcare) equilibrated with the 
dissolving buffer. Proteins bound to the resin were eluted by 
decreasing the pH to 4.5. The eluate was conditioned by 
adjusting pH and adding dithiothreitol (DTT) at a concentra 
tion of 20 mM. The conditioned eluate was slowly diluted into 
1 L of refolding buffer; 50 mM Tris-HCl, pH 8, 0.5 Margin 
ine, 20 mM DTT, followed by incubation for 2 days at 4°C. 
The diluted sample was concentrated and buffer-exchanged 
into 20 mM Tris-HCl, pH 9 using an ultrafiltration method. 
The concentrated sample was loaded onto a 10 mL column of 
Qsepharose fast flow resin (GE Healthcare) equilibrated with 
20 mM Tri-HCl (pH9). 
0254. After washing the resin with the equilibration 
buffer, proteins bound to the resin were eluted with 20 mM 
Tris-HCl, pH 9, 500 mM. NaCl. To remove the cleaved off 
His-N' fusion fragment and any uncleaved fusion protein 
from the refolded FGF21 protein, the eluate was loaded onto 
a 5 mL column of Ni-NTA high performance resin equili 
brated with 20 mM Tris, pH 8.0, 50 mM imidazole, and the 
flow-through fraction containing FGF21 was collected. To 
reduce endotoxin levels, the FGF21 fraction was treated with 
an EndoTrap HD resin (Hyglos) equilibrated with 10 mM 
Tris, pH 8,50 mM imidazole, 500 mM. NaCl, 1 mM CaCl. 
The low-endotoxin sample was dialyzed against PBS and 
then sterilized with a 0.22 um filter. The purified FGF21 
protein was Snap-frozen in liquid nitrogen and stored at -80° 
C. Protein concentration was determined by absorbance at 
280 nm using 93.62 M-1 cm-1 as the molar extinction coeffi 
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cient for FGF21. Protein purity and integrity were determined 
by HPLC, SDS-PAGE and liquid chromatography-mass 
spectrometry. 
0255 Cysteine PEGylation of FGF21 Variants: 
0256 FGF21 Variant V76 (R154C) variant has the ten 
dency to dimerize via the engineered cysteine; therefore, 
prior to PEGylation the protein solution (typically 5 mg/mL 
in Tris buffer) was mildly reduced with 5 mM mercaptoethy 
lamine for 30 minutes on ice and immediately desalted in 20 
mM Tris, pH 7. The freshly reduced protein (typically 3 
mg/mL) was then immediately PEGylated with 1.5 equiva 
lent of 40 kDa branched maleimido-PEG reagent (NOF, Cat. 
#GL2-400MA from the Sunbright series) for 3 hours on ice. 
The PEGylated protein was finally purified by anion 
exchange chromatography (MonoC) with overall yields of 
about 25%. 
0257 Expression Constructs for Fc-FGF21 Fusion Vari 
antS: 
0258. The cDNAs for human FGF21 variants encoding 
amino acids 33-209 were cloned into a mammalian expres 
sion vector downstream of the cytomegalovirus (CMV) pro 
moter in-frame with N-terminal sequences including a leader 
peptide (immunoglobulin kappa-chain) to direct secretion of 
the proteins, followed by an Fc domain and a short linker. 
0259 Expression and Purification of Fc-FGF21 Variants: 
0260 The Fc-FGF21 variant proteins were expressed into 
HEK293T cells (American Type Culture Collection). Cells 
were grown in suspension culture at 37° C., 8% CO, in 
Freestyle 293 Expression Medium (Invitrogen, Cat. #12338 
018) until day of transfection. Cells were centrifuged at 
1000xg for 7 min in a swinging bucket rotor and counted 
using an automated cell counter. Cells were diluted in 900 mL 
of Freestyle 293 media to a final concentration of 1.4x10' 
cells/mL and placed into a 3 L non-baffled flask (Corning, 
Cat. #431252). Cells were transfected using a mixture of 
polyethyleneimine (PEI) and plasmid as follows. Three mL 
of a sterile 1 mg/mL stock of linear, M.W. 25,000, PEI (Alfa 
Aesar, Cat. #43896) was added to 50 mL of Freestyle 293 
media, mixed gently and incubated at 25°C. for 5 minutes. At 
the same time, 1 mg of endotoxin-free plasmid was added to 
50 mL Freestyle 293 media and sterile filtered using a 0.22 
uM filter. The PEI mixture was then added to the sterile 
filtered DNA, mixed gently and allowed to incubate at 25°C. 
for 10 minutes. The PEI-plasmid mixture was then added to 
the 3 L flask containing the diluted HEK 293T cells and 
placed at in a shaking incubator at 125 RPM, 37°C., 8% CO. 
0261) On day 6 post-transfection, the cells were centri 
fuged at 2000xg for 10 minutes and the supernatant was 
harvested. The supernatant was further clarified by filtration 
through a 0.8/0.2 uM filter (Pall Corporation, Cat. #4628). 
0262 Batch purification of the FGF21 protein was done 
by adding 1 mL of recombinant Protein A Sepharose Fast 
Flow (GE, Cat. #17-5138-03), per 20 mg of expected protein 
to be purified, directly to the clarified supernatant and incu 
bating for 1 hour at 4°C. with gentle rotation. The supernatant 
mixture was then poured over a disposable Poly-Prep Chro 
matography Column (Bio-Rad, Cat. #731-1550) and the flow 
through was discarded. The retained beads were washed with 
5 column volumes of DPBS, pH7.4 (Invitrogen, Cat. #14190 
144). Elution of the protein from the Protein A beads was 
done by adding 20 column volumes of 50 mMSodium Citrate 
buffer, pH 3.0. The elution buffer was neutralized by the 
addition of 20% Tris-HCL buffer, pH 9.0. Size exclusion 
chromatography was preformed as a secondary polishing step 
Mar. 28, 2013 
by running the Protein Abatch purified material over a High 
Load 26/600 Superdex 200 pg column (GE, Cat. #28-9893 
36). The purified protein yield was quantified by A280. SDS 
Page was run to Verify purity and molecular weight. Endot 
oxin level was quantified by using the Endosafe PTS system 
(Charles River Labs). 
Example 2 
Measuring FGF21 Dependent 2-Deoxyglucose 
(2-DOG) Uptake 
0263 FGF21 has been shown to stimulate glucose-uptake 
in mouse 3T3-L1 adipocytes in the presence and absence of 
insulin, and to decrease fed and fasting blood glucose, trig 
lycerides, and glucagon levels in ob/ob and db/db mice and 8 
week old ZDF rats in a dose-dependent manner, thus, provid 
ing the basis for the use of FGF21 as a therapy for treating 
diabetes and obesity (see, e.g., patent publication WO03/ 
011213, and Kharitonenkov et al., (2005) Jour. of Clinical 
Invest. 115:1627-1635). Also, FGF21 was observed to stimu 
late tyrosine phosphorylation of FGFR-1 and FGFR-2 in 
3T3-L1 adipocytes. 
0264. T3-L1 fibroblasts were purchased from ATCC (Cat. 
#CL173). The cells were grown to confluency in 150 cm 
petri-dish and were maintained in DMEM with high glucose 
(Invitrogen, Cat. #11995065) supplemented with 10% Fetal 
Bovine Serum and 1% penicillin-streptomycin for an addi 
tional 4 days. Cells were then differentiated in the above 
media Supplemented with 4 g/mL insulin (Sigma, Cat. 
#1-5500), 115 g/mL IBMX (Sigma, Cat. #15879) and 
0.0975 ug/mL dexamethasone (Sigma, Cat. HD 1756) for 3 
days after which the differentiation media was replaced with 
complete DMEM. One plate of differentiated 3T3-L1 adipo 
cytes were seeded into four 96-well plates the day after 
medium replacement. 
0265. The adipocytes were then treated with FGF21-WT 
and FGF21 variant protein (see Table 2 for list of variants; 30 
pM to 100 nM is the typical concentration range used) over 
night in complete medium. The adipocytes treated with 
FGF21 samples were serum starved in 50 uL per well KRH 
buffer (0.75% NaCl; 0.038%. KCl; 0.0196% CaC1; 0.032% 
MgSO, 0.025M HEPES, pH 7.5; 0.5% BSA; 2 mM sodium 
pyruvate) for 2 hours. The wells for blank were added with 1 
LL (final concentration 5 Jug/ml) cytochalasin B for 15 min. 
[3H]-2-DOG (20.6 mCi/mmoL, 1 mCi/mL) was diluted 1:20 
in 5.1 mM cold 2-DOG and 1 uL diluted 2-DOG was added 
per well and the cells were incubated for 5 min. The cells were 
washed with 100 uL/well KRH buffer three times. 40 uL/well 
1% SDS was added to cells and the cells were shaken for at 
least 10 minutes. 200 u/well scintillation fluid was added 
and the plates were shaken overnight and read in beta-micro 
plate reader. The values obtained from an entire column/row, 
which were treated with cytochalasin B, was averaged and 
subtracted from all other values. The data were analyzed by 
GraphPad Prism software, the results of which are summa 
rized in Table 2. Fc-FGF21 Fusion Variants V101, V103 and 
V188 are superior to PEGylated FGF21 Variant V76 in for 
induction of 2-deoxyglucose uptake by mouse 3T3L1 adipo 
cytes. 
Example 3 
pERK In Cell Western (ICW) Assay 
0266 HEK293 cells stably transfected with human 
B-klotho were cultured in DMEM high glucose, 10% FBS, 
US 2013/007.9500 A1 
1% PS and 600 ng/mL G418 are seeded in poly-D-lysine 
coated 96-well plates (BD bioscience, Cat. #356640) at 
30,000 cells per well overnight. The cells were serum starved 
in DMEM high glucose, 0.5% BSA and 10 mM HEPES for 4 
hours. WTFGF21 and the FGF21 variants (see Table 3 for list 
of variants) were diluted to various concentrations (100 pM to 
300 nM is the typical concentration range used) in starvation 
medium. The cells were stimulated with FGF21 for 10 min 
utes. Following FGF21 or FGF21 Variant protein stimulation, 
the media was aspirated from the wells and the cells were 
washed once with 100 uL cold PBS and then fixed with 100 ul 
of 4% formaldehyde for 15 minutes at room temperature and 
followed by an additional 10 minute incubation with 100 uL 
ice-cold methanol. 
0267. After fixation, the cells were washed with 0.3% 
Triton X-100 in PBS four times, 5 minutes each. 150 uL 
Odyssey Blocking Buffer was added to the permeabilized 
cells at room temperature for 1.5 hours. Phospho-ERK 
(pERK) antibody was diluted to a concentration of 0.17 
ug/mL (1:200 dilution, or the dilutions indicated), and total 
ERK (tRK) antibody was diluted to a concentration of 2.2 
ug/mL (1:200 dilution, or the dilutions indicated) in Odyssey 
Blocking Buffer. 50LL was added to every well, omitting one 
column which was only treated with secondary antibody to 
normalize for background. The plate was covered with the 
wet paper tower and lid to prevent evaporation and then 
incubated at 4°C. overnight. 
0268. Afterwards, the primary antibody was aspirated and 
the cells were washed four times with 0.3% Tween 20 in PBS 
for 5 minutes each. During the washing, the secondary anti 
body reaction mixture was prepared in Odyssey Blocking 
Buffer containing 1:1000-diluted (or the dilutions indicated) 
goat anti-mouse Alexa 680 and 1:1000-diluted (or the dilu 
tions indicated) IRDye800 goat anti-rabbit antibody. Once 
the washing was completed, 40 uL of the reaction mixture 
was added to each well. Plates were covered with black lid to 
protect the secondary antibody from light, and plates were 
incubated at room temperature for 1 hour on a shaker. Finally, 
the cells were washed again four times with 0.3% Tween 20 in 
PBS for 5 minutes each and then scanned on the LI-COR 
Bioscience Odyssey Infrared Imaging System (Li-Cor Bio 
sciences, Lincoln, Nebr.) in the 700 nm (red) and 800 nm 
(green) channels. Alexa 680 stained the tERK with far-red 
fluorescence (emission wavelength 668 nm), while 
IRDye800 stained the pERK with green fluorescence (emis 
sion wavelength 800 nm). To eliminate the fluorescent back 
ground, the values obtained from an entire column/row, 
which was treated with only secondary antibody, was aver 
aged and subtracted from all other values obtained from the 
plate. For normalization of the amount of pH.RK present in 
each sample, the values for pERK in each well was divided by 
the values of tERK. The data were analyzed by GraphPad 
Prism software, the results of which are summarized in Table 
2. Fc-FGF21 Fusion Variants V101, V103 and V188 are supe 
rior to PEGylated FGF21 Variant V76 in this ERK phospho 
rylation assay. 
TABLE 2 
Summary of ERK in cell Western and Mouse 3T3L1 
Adipocyte Glucose Uptake ASSay Results 
pERK Glucose Uptake 
FGF21 (HEK293/human B-klotho) (Mouse 3T3L1 adipocytes) 
Variant ID ECSO SEM ECSO SEM 
V76 13 + 4 nM (n = 5) 5 + 1 nM (n = 3) 
V101 0.60 + 0.06 nM (n = 5) 0.60 + 0.06 nM (n = 3) 
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TABLE 2-continued 
Summary of ERK in cell Western and Mouse 3T3L1 
Adipocyte Glucose Uptake ASSay Results 
pERK Glucose Uptake 
FGF21 (HEK293/human B-klotho) (Mouse 3T3-L1 adipocytes) 
Variant ID ECSO SEM ECSO SEM 
V103 0.9 + 0.3 nM (n = 5) 0.60 + 0.07 nM (n = 3) 
W188 0.4 + 0.1 nM (n = 3) 0.48 + 0.14 nM (n = 3) 
Example 4 
In Vivo Tests of FGF21 Variants 
0269. The ob?ob mouse is a mouse model for type 2 dia 
betes. The mice lack functional leptin and are characterized 
by hyperglycemia, insulin resistance, hyerphagia, hepatic Ste 
atosis and obesity. Male ob?ob mice (10-13 weeks old) were 
used to measure the effect on blood glucose of the following 
PEGylated FGF21 variant V76 and Fc-FGF21 fusion variants 
V101, V103 and V188. 
0270 FGF21 variants or PBS vehicle were administered 
s.c. at 1 mg/kg (V101, V103 and V188) or s.c at 5 mg/kg V76 
twice per week 12 days (4 doses total). On the first day of the 
study, tail blood glucose and body weight were measured and 
mice were allocated into different groups (n=8 per group) 
with mean glucose and body weight matched among the 
groups. Blood glucose was measured using a glucometer 
(OneTouch). Plasma insulin was measured on day 1 before 
dosing and on day 12, 24 hours post the last dose. The results 
of these studies are summarized in Table 5. 
0271 The results of these studies are summarized in Table 
3 and FIGS. 1-3. Fc-FGF21 Fusion Variants V101, V103 and 
V188 are superior to PEGylated FGF21 Variant V76 on every 
endpoint measured in these studies and at a five-fold lower 
dose. 
TABLE 3 
% changes versus vehicle in plasma glucose, insulin, 
body weight (BW) gain, liver TG/lipid by FGF21 
variants during 12-day studies in objob mice. 
Summary of 12-day treatment study in diabetic ob?ob mice 
% change from vehicle 
Total 
FGF21 Dose Glucose Plasma Body Liver 
Variant ID (mg/kg) (AUC) Insulin Weight lipid 
V76 S.O -42% -46% -7% -30% 
V101 1.O -53% -82% -1.2% -44% 
V103 1.O -46% -69% -1.2% -50% 
W188 1.O -42% -59% -1.1% -51% 
Example 5 
Pharmacokinetics of FGF21 Fusion Variants in Mice 
0272. To determine the pharmacokinetic profile of Fc 
FGF21 Fusion Variants V101, V103 and V188, C57BL/6J 
mice were injected IV with 1 mg/kg test article and bled at 
various time points out to 16 days (384 hours). Blood samples 
were collected into EDTA-coated microtainer tubes from 
either the submandibular or retro-orbital plexus. Approxi 
mately 50 uL of blood was collected at each time point, 
yielding ~25 uL of plasma. 
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0273 To measure plasma concentrations of testarticles by 
ELISA, 384-well plates were coated overnight at room tem 
perature (RD with 2 g/mL of anti-Human Fc-gamma goat 
polyclonal antibody (30 uL/well) and then blocked with a 
casein-based diluent for 2 hour at RT (100 uL/well). Diluted 
samples, standards, and controls were added to the plate (30 
uL/well) and incubated for 2 hour at RT. After the samples 
were removed, the wells were washed 3 times with a phos 
phate-based wash solution (100LL?well). The detection anti 
body, an HRP-labeled version of the capture antibody, was 
added to the plate and incubated for 1 hour at RT (30LL?well). 
After the plate was again washed 3 times with a phosphate 
based wash solution (100 uL/well), a chemiluminescent sub 
strate was added (30 uI/well) and the plate luminescence was 
read within 5 minutes using an appropriate plate reader. As 
shown in FIGS. 4A and 4B the Fc-FGF21 fusion variants had 
a greatly extended plasma half-life relative to known Fc 
FGF21 fusions in the art (FIG. 4A) and relative to PEGylated 
FGF21 variant V76 (FIG. 4B). 
0274 Serum levels of Fc-FGF21 test articles were vali 
dated by Western blot for comparison to levels measured by 
ELISA to ensure that full length Fc-FGF21 variant and not Fc 
alone was being detected in the ELISA. Two ul of mouse 
serum was combined with 2.5uL of 4x loading buffer, 1 uL of 
10x denaturant and 4 uL of dHO, heated to 95°C. for 5 
minutes and loaded onto a 4-12% gradient polyacrylamide 
gel and electrophoresed for 1 hour at 100 Volts (constant 
voltage). Samples were transferred to nitrocellulose filter 
paper by Western blot using the iblot system (Invitrogen, Cat. 
#IB1001, 7 minute run time). The nitrocellulose filters were 
blocked with 30 mL of Rockland blocking solution (Cat. 
#MB-070), probed following the snap iblot system protocol 
with a goat anti-FGF21 primary antibody at a 1:2000 dilution 
(R&D systems, Cat. iBAF2539) and fluorescently labeled 
streptavidin as a secondary at a 1:10000 dilution (Licor, Cat. 
#926-68031). Protein levels were imaged on the Licor Odys 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS : 13 
SEO ID NO 1 
LENGTH: 209 
TYPE PRT 
ORGANISM: Homo sapiens 
<4 OOs SEQUENCE: 1 
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sey system at 700 nm and compared with 2 nM control V101 
run on the same gel. As shown in FIG. 4C full-length Fc 
FGF21 variants V101, V103 and V188 are detectable using on 
a Western Blot using anti-FGF21 antibody out to 15 days 
from mouse serum from the pharmacokinetic study. 
Example 6 
Fc-FGF21 Fusion Variants V101, V103 and V188 are 
Extremely Thermodynamically Stabile 
0275 Proteins can be unfolded at specific temperature 
range. The temperature of protein unfolding is an intrinsic 
parameter to describe thermal stability of proteins. Differen 
tial Scanning calorimetry (DSC) is used to detect the unfold 
ing temperature of protein. This characteristic temperature is 
described as melting temperature (Tm), which is the peak 
temperature during protein unfolding. 
0276 Original protein samples are diluted in PBS to a 
concentration of ~ 1 mg/ml (0.5 mg/ml to 1.2 mg/ml) for a 
total volume of 0.5 ml. An aliquot of 0.4 ml per well diluted 
protein sample, standard, PBS, and DI water are added to 
DSC 96-well plate. The plate is then covered by a seal. 
Samples were analyzed in a 96 well Differential Scanning 
calorimeter from MicroCal. The temperature was scanned 
from 10-110 degrees C. at a rate of 1 degree per minute. 
0277 As shown in FIG. 4D the melting temperatures of 
FGF21 variants V101, V103 and V188 are extremely high. 
This is in contrast to the lower melting temperatures of 
FGF21 variant V76 and wild-type FGF21 (not shown). We 
attribute the improved stability of V101, V103 and V188 to 
the specific addition of a second disulfide bond from the novel 
Q55C and G148C mutations. This type of thermodynamic 
stability is known to protect proteins from proteolysis and can 
in addition translate into significantly prolonged Stability in 
vivo and the improved pharmacokinetic profiles exemplified 
by the data in FIGS. 4B and 4C. 
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- Continued 
1OO 105 11 O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
115 12 O 125 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
13 O 135 14 O 
His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Pro Arg Gly 
145 150 155 160 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
1.65 17O 17s 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
18O 185 19 O 
Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
195 2OO 2O5 
Ser 
<210s, SEQ ID NO 2 
&211s LENGTH: 940 
&212s. TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 2 
Ctgtcagctg aggatc.ca.gc cgaaagagga gcc aggcact caggccacct gag to tactic 6 O 
acctggacaa citggaatctg gcaccaattic taalaccactic agcttct cog agct cacacc 12 O 
ccggagat.ca cctgaggacc cago cattg atggact cqg acgaga.ccgg gttcgagcac 18O 
t caggactgt gggitttctgt gctggctggt Cttctgctgg gag cctgcca ggcacaccc.c 24 O 
atcCctgact C cagtic ct ct cctgcaattic gggggccaag ticcggcagcg gtacctic tac 3OO 
acagatgatg cccagcagac agaag.cccac ctggagat.ca gggaggatgg gacggtgggg 360 
ggcgctgctg accagagc cc caaagttctic Ctgcagctga aagccttgaa gCCgggagtt 42O 
attcaaatct tdgagt caa gaCat CCagg ttcctgtgcc agcggccaga tigggg.ccctg 48O 
tatggat.cgc. tcc actittga C cctgaggcc ticagottcc gggagctgct tcttgaggac 54 O 
ggatacaatgtttaccagtic Caag.cccac ggcct cocgc tigcacct gcc agggaacaag 6OO 
tcc.ccacacc gggaccCtgc accc.cgagga C cagct cqct tcc ticcact accaggcctg 660 
CCCC cc.gcac toccggagcc acccggaatc Ctggc.ccc.cc agc.ccc.ccga tigtgggct cc 72 O 
tcggaccctic taggatggt gggacct tcc Cagggcc.gala gcc cc agct a cqctt CCtga 78O 
agccagaggc tigtttact at gacat citcct ctittattitat taggittattt atc.ttattta 84 O 
tttittt tatt tttct tactt gagataataa agagttccag aggagaaaaa aaaaaaaaaa 9 OO 
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa. 94 O 
<210s, SEQ ID NO 3 
&211s LENGTH: 181 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 3 
His Pro Ile Pro Asp Ser Ser Pro Leu Lieu. Glin Phe Gly Gly Glin Val 
1. 5 1O 15 
Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His 
2O 25 3O 
Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser 
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- Continued 
35 4 O 45 
Pro Glu Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin 
SO 55 6 O 
Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly 
65 70 7s 8O 
Ala Lieu. Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg 
85 90 95 
Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His 
1OO 105 11 O 
Gly Lieu Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro 
115 12 O 125 
Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Lieu Pro Pro 
13 O 135 14 O 
Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val 
145 150 155 160 
Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser 
1.65 17O 17s 
Pro Ser Tyr Ala Ser 
18O 
<210s, SEQ ID NO 4 
&211s LENGTH: 546 
&212s. TYPE: DNA 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 4 
Caccc.cat co Ctgacticcag ticct Ctcct caatt.cgggg gccaagt ccg gcagcgg tac 6 O 
Ctct acacag atgatgcc.ca gcagacagaa goccacctgg agat Caggga ggatgggacg 12 O 
gtgggggg.cg Ctgctgacca gagcc.ccgala agt ct cotgc agctgaaagc Cttgaag.ccg 18O 
ggagittatt c aaatcttggg agt caagaca toc aggttcc titgc.ca.gcg gcc agatggg 24 O 
gccCtgtatg gat.cgcticca Ctttgaccct gaggcctgca gct tccggga gctgctt Ctt 3OO 
gaggacggat acaatgttta C cagt ccgala gcc cacggcc ticcc.gctgca CctgcCaggg 360 
aacaagtic cc cacaccggga ccctgcaccc cdaggaccag citcqct tcct gcc actacca 42O 
ggcctgcc cc cc.gcactic cc ggagccaccc ggaatcc tig C cc cc cagcc ccc.cgatgtg 48O 
ggct cotcgg accctctgag catggtggga cct tccCagg gcc.gaag.ccc cagctacgct 54 O 
t cct ga 546 
<210s, SEQ ID NO 5 
&211s LENGTH: 28 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 5 
Met Asp Ser Asp Glu Thr Gly Phe Glu. His Ser Gly Lieu. Trp Val Ser 
1. 5 1O 15 
Val Lieu Ala Gly Lieu. Lieu. Lieu. Gly Ala Cys Glin Ala 
2O 25 
<210s, SEQ ID NO 6 
&211s LENGTH: 15 
&212s. TYPE: DNA 
<213> ORGANISM: Homo sapiens 
US 2013/007.9500 A1 
<4 OOs, SEQUENCE: 6 
ggggsggggs ggggs 
<210s, SEQ ID NO 7 
&211s LENGTH: 406 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OO > SEQUENCE: 7 
Asp Llys Thr His Thr Cys Pro 
1. 5 
Gly Pro Ser Val Phe Leu Phe 
2O 
Ile Ser Arg Thr Pro Glu Val 
35 
Glu Asp Pro Glu Val Llys Phe 
SO 55 
His Asn Ala Lys Thr Llys Pro 
65 70 
Arg Val Val Ser Val Lieu. Thr 
85 
Lys Glu Tyr Lys Cys Llys Val 
1OO 
Glu Lys Thr Ile Ser Lys Ala 
115 
Tyr Thr Lieu Pro Pro Ser Arg 
13 O 135 
Lieu. Thir Cys Lieu Val Lys Gly 
145 150 
Trp. Glu Ser Asn Gly Glin Pro 
1.65 
Val Lieu. Asp Ser Asp Gly Ser 
18O 
Asp Llys Ser Arg Trp Glin Glin 
195 
His Glu Ala Lieu. His Asn His 
21 O 215 
Pro Gly Lys Gly Ser Asp Ser 
225 23 O 
Val Arg Glin Arg Tyr Lieu. Tyr 
245 
His Lieu. Glu Ile Arg Glu Asp 
26 O 
Ser Pro Glu Ser Lieu Lleul Glin 
27s 
Glin Ile Lieu. Gly Val Llys Thr 
29 O 295 
Gly Ala Lieu. Tyr Gly Ser Lieu. 
3. OS 310 
Arg Glu Lieu. Lieu. Lieu. Glu Asp 
3.25 
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Pro Ala Pro Arg Gly Pro Ala Arg Phe Leu Pro Leu Pro Gly Lieu Pro 
355 360 365 
Pro Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp 
37 O 375 38O 
Val Gly Ser Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg 
385 390 395 4 OO 
Ser Pro Ser Tyr Ala Ser 
4 OS 
<210s, SEQ ID NO 8 
&211s LENGTH: 419 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 8 
Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 
1. 5 1O 15 
Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met 
2O 25 3O 
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
35 4 O 45 
Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
SO 55 6 O 
His Asn Ala Lys Thr Llys Pro Arg Glu Glu Gln Tyr ASn Ser Thr Tyr 
65 70 7s 8O 
Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly 
85 90 95 
Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile 
1OO 105 11 O 
Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val 
115 12 O 125 
Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser 
13 O 135 14 O 
Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
145 150 155 160 
Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
1.65 17O 17s 
Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val 
18O 185 19 O 
Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met 
195 2OO 2O5 
His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser 
21 O 215 22O 
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
225 23 O 235 24 O 
Gly Ser Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin 
245 250 255 
Arg Tyr Lieu. Tyr Thr Asp Asp Ala Glin Glin Thr Glu Ala His Lieu. Glu 
26 O 265 27 O 
Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu 
27s 28O 285 
Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. 
29 O 295 3 OO 
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Gly Val Lys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly Ala Lieu. 
3. OS 310 315 32O 
Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. 
3.25 330 335 
Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu. 
34 O 345 35. O 
Pro Lieu. His Lieu Pro Gly Asn Llys Ser Pro His Arg Asp Pro Ala Pro 
355 360 365 
Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro Pro Ala Lieu 
37 O 375 38O 
Pro Glu Pro Pro Gly Ile Leu Ala Pro Glin Pro Pro Asp Val Gly Ser 
385 390 395 4 OO 
Ser Asp Pro Leu Ser Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser 
4 OS 41O 415 
Tyr Ala Ser 
<210s, SEQ ID NO 9 
&211s LENGTH: 177 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 9 
Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin Arg Tyr 
1. 5 1O 15 
Lieu. Tyr Thr Asp Asp Ala Glin Glu Thr Glu Ala His Lieu. Glu Ile Arg 
2O 25 3O 
Glu Asp Gly Thr Val Gly Gly Ala Ala His Glin Ser Pro Glu Ser Lieu. 
35 4 O 45 
Lieu. Glu Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. Gly Val 
SO 55 6 O 
Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. Tyr Gly 
65 70 7s 8O 
Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. Lieu. Lieu. 
85 90 95 
Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu Pro Lieu. 
1OO 105 11 O 
His Leu Pro Gly Asn Arg Ser Pro His Cys Asp Pro Ala Pro Glin Gly 
115 12 O 125 
Pro Ala Arg Phe Lieu Pro Leu Pro Gly Leu Pro Pro Ala Leu Pro Glu 
13 O 135 14 O 
Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp Val Gly Ser Ser Asp 
145 150 155 160 
Pro Leu Ala Met Val Gly Pro Ser Glin Gly Arg Ser Pro Ser Tyr Ala 
1.65 17O 17s 
Ser 
<210s, SEQ ID NO 10 
&211s LENGTH: 406 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 10 
Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 
1. 5 1O 15 
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Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met 
2O 25 3O 
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
35 4 O 45 
Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
SO 55 6 O 
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
65 70 7s 8O 
Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly 
85 90 95 
Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile 
1OO 105 11 O 
Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val 
115 12 O 125 
Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser 
13 O 135 14 O 
Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
145 150 155 160 
Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
1.65 17O 17s 
Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val 
18O 185 19 O 
Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met 
195 2OO 2O5 
His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser 
21 O 215 22O 
Pro Gly Lys Gly Ser Asp Ser Ser Pro Leu Lleu Glin Phe Gly Gly Glin 
225 23 O 235 24 O 
Val Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala 
245 250 255 
His Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin 
26 O 265 27 O 
Ser Pro Glu Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile 
27s 28O 285 
Glin Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp 
29 O 295 3 OO 
Gly Thr Lieu. Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe 
3. OS 310 315 32O 
Arg Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala 
3.25 330 335 
His Gly Lieu Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp 
34 O 345 35. O 
Pro Ala Ser Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro 
355 360 365 
Pro Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp 
37 O 375 38O 
Val Gly Ser Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg 
385 390 395 4 OO 
Ser Pro Ser Tyr Ala Ser 
4 OS 
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<210s, SEQ ID NO 11 
&211s LENGTH: 406 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 11 
Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 
1. 5 1O 15 
Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met 
2O 25 3O 
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
35 4 O 45 
Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
SO 55 6 O 
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
65 70 7s 8O 
Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly 
85 90 95 
Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile 
1OO 105 11 O 
Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val 
115 12 O 125 
Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser 
13 O 135 14 O 
Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
145 150 155 160 
Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
1.65 17O 17s 
Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val 
18O 185 19 O 
Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met 
195 2OO 2O5 
His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser 
21 O 215 22O 
Pro Gly Lys Gly Ser Asp Ser Ser Pro Leu Lleu Glin Phe Gly Gly Glin 
225 23 O 235 24 O 
Val Arg Glin Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala 
245 250 255 
His Lieu. Glu Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin 
26 O 265 27 O 
Ser Pro Glu Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile 
27s 28O 285 
Glin Ile Lieu. Gly Val Llys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp 
29 O 295 3 OO 
Gly Ala Leu Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe 
3. OS 310 315 32O 
Arg Glu Lieu. Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala 
3.25 330 335 
His Gly Lieu Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp 
34 O 345 35. O 
Pro Ala Ser Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro 
355 360 365 
Pro Ala Leu Pro Glu Pro Pro Gly Ile Leu Ala Pro Gln Pro Pro Asp 
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37 O 375 38O 
Val Gly Ser Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg 
385 390 395 4 OO 
Ser Pro Ser Tyr Ala Ser 
4 OS 
<210s, SEQ ID NO 12 
&211s LENGTH: 419 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 12 
Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 
1. 5 1O 15 
Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met 
2O 25 3O 
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
35 4 O 45 
Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
SO 55 6 O 
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
65 70 7s 8O 
Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly 
85 90 95 
Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile 
1OO 105 11 O 
Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val 
115 12 O 125 
Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser 
13 O 135 14 O 
Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
145 150 155 160 
Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
1.65 17O 17s 
Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val 
18O 185 19 O 
Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met 
195 2OO 2O5 
His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser 
21 O 215 22O 
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
225 23 O 235 24 O 
Gly Ser Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin 
245 250 255 
Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu 
26 O 265 27 O 
Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu 
27s 28O 285 
Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. 
29 O 295 3 OO 
Gly Val Lys Thir Ser Arg Phe Lieu. Cys Glin Llys Pro Asp Gly Ala Lieu. 
3. OS 310 315 32O 
Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. 
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3.25 330 335 
Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu. 
34 O 345 35. O 
Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser 
355 360 365 
Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro Pro Ala Lieu 
37 O 375 38O 
Pro Glu Pro Pro Gly Ile Leu Ala Pro Glin Pro Pro Asp Val Gly Ser 
385 390 395 4 OO 
Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg Ser Pro Ser 
4 OS 41O 415 
Tyr Ala Ser 
<210s, SEQ ID NO 13 
&211s LENGTH: 419 
212. TYPE: PRT 
<213> ORGANISM: Homo sapiens 
<4 OOs, SEQUENCE: 13 
Asp Llys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 
1. 5 1O 15 
Gly Pro Ser Val Phe Leu Phe Pro Pro Llys Pro Lys Asp Thr Lieu Met 
2O 25 3O 
Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 
35 4 O 45 
Glu Asp Pro Glu Val Llys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 
SO 55 6 O 
His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 
65 70 7s 8O 
Arg Val Val Ser Val Lieu. Thr Val Lieu. His Glin Asp Trp Lieu. Asn Gly 
85 90 95 
Lys Glu Tyr Lys Cys Llys Val Ser Asn Lys Ala Lieu Pro Ala Pro Ile 
1OO 105 11 O 
Glu Lys Thir Ile Ser Lys Ala Lys Gly Glin Pro Arg Glu Pro Glin Val 
115 12 O 125 
Tyr Thr Lieu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Glin Val Ser 
13 O 135 14 O 
Lieu. Thir Cys Lieu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 
145 150 155 160 
Trp. Glu Ser Asn Gly Glin Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 
1.65 17O 17s 
Val Lieu. Asp Ser Asp Gly Ser Phe Phe Lieu. Tyr Ser Llys Lieu. Thr Val 
18O 185 19 O 
Asp Llys Ser Arg Trp Glin Glin Gly Asn Val Phe Ser Cys Ser Val Met 
195 2OO 2O5 
His Glu Ala Lieu. His Asn His Tyr Thr Glin Llys Ser Lieu. Ser Lieu. Ser 
21 O 215 22O 
Pro Gly Lys Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly 
225 23 O 235 24 O 
Gly Ser Asp Ser Ser Pro Lieu. Lieu. Glin Phe Gly Gly Glin Val Arg Glin 
245 250 255 
Arg Tyr Lieu. Tyr Thr Asp Asp Ala Cys Glin Thr Glu Ala His Lieu. Glu 
26 O 265 27 O 
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Ile Arg Glu Asp Gly Thr Val Gly Gly Ala Ala Asp Glin Ser Pro Glu 
27s 28O 285 
Ser Lieu. Lieu. Glin Lieu Lys Ala Lieu Lys Pro Gly Val Ile Glin Ile Lieu. 
29 O 295 3 OO 
Gly Val Lys Thir Ser Arg Phe Lieu. Cys Glin Arg Pro Asp Gly. Thir Lieu. 
3. OS 310 315 32O 
Tyr Gly Ser Lieu. His Phe Asp Pro Glu Ala Cys Ser Phe Arg Glu Lieu. 
3.25 330 335 
Lieu. Lieu. Glu Asp Gly Tyr Asn Val Tyr Glin Ser Glu Ala His Gly Lieu. 
34 O 345 35. O 
Pro Lieu. His Lieu Pro Cys Asn Arg Ser Pro His Arg Asp Pro Ala Ser 
355 360 365 
Arg Gly Pro Ala Arg Phe Lieu Pro Lieu Pro Gly Lieu Pro Pro Ala Lieu 
37 O 375 38O 
Pro Glu Pro Pro Gly Ile Leu Ala Pro Glin Pro Pro Asp Val Gly Ser 
385 390 395 4 OO 
Ser Asp Pro Lieu Ala Met Val Gly Gly Ser Glin Ala Arg Ser Pro Ser 
4 OS 41O 415 
Tyr Ala Ser 
What is claimed is: 
1. A fusion protein comprising an FGF21 variant and an Fc 
region. 
2. The fusion protein of claim 1, wherein the sequence of 
said protein is selected from a sequence listed in Table 1. 
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